Electroporation device and method for cell transfection

Abstract

An improved electroporation medium is provided for electroporation of mammalian and non-mammalian cells, particularly for high-throughput large-scale manufacturing processes. [Solution] An electroporation medium comprising one or more salts, a monosaccharide, and a buffer, wherein the salts are selected from the group consisting of metal halide salts, phosphate salts, metal sulfate salts, and combinations thereof.

Description

Detailed Description of the Invention

[0001] [Technical field] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. § 365(c) from International Patent Application No. PCT / US2019 / 041055, filed July 9, 2019, the entire contents of which are incorporated herein by reference.

[0002] The field of the invention relates to transfection systems and methods, in particular electroporation systems and methods. [Background technology] The Background Description includes information that may be useful in understanding the methods and techniques presented herein. No admission is made that any of the information provided herein is prior art or related to the subject matter presented herein, or that any publication referenced, expressly or impliedly, is prior art.

[0003] Transfection may be used to introduce nucleic acids into cells and generate genetically modified cells. A variety of physical, chemical, and viral methods exist for transfecting cells, including optoperforation, polymer-based methods utilizing calcium phosphate, microinjection, electroporation, viral transduction, and lipid-mediated methods (e.g., using liposome-DNA complexes).

[0004] Electroporation involves the application of controlled direct current (DC) electric pulses of relatively short duration to cells. The electric pulse is believed to induce a membrane potential that causes a reversible disintegration of the ordered structure of the cell membrane, resulting in the formation of pores in the membrane. Molecules of interest can then enter the cell through the pores until the pores close, typically within milliseconds to seconds. Pore formation can be controlled by adjusting various parameters, in particular the gap width (e.g., the distance between the parallel electrode plates), the shape of the electric pulse wave, the electric field strength, the temperature, and the electric pulse length.

[0005] Electroporation is commonly used at laboratory scale (e.g., using small cuvettes with a capacity of about 0.5 mL), but such laboratory-based techniques are not suitable for large-scale clinical-grade production due to reduced efficiency and high cost. Other transfection methods, such as lipid-based techniques using Lipofectamine 2000™, are also frequently used, but have similar drawbacks due to high cost. In addition, lipid-based methods do not work well for some cell types of clinical interest, such as NK cells, such as haNK. NK cells have been transfected using mRNA and electroporation, for example, by genetically engineering primary NK cells to express chimeric antigen receptors (CARs - see Non-Patent Document 1) or to express cytokines for autocrine growth stimulation (see Non-Patent Document 2). While commercial products such as Maxcyte exist for large-scale transfection (e.g., reaction sizes larger than 1 mL), these products are also expensive and / or lack high-throughput capabilities. Similarly, these commercial products are not optimal for transfecting NK cells and often result in problems with low yields and / or low cell viability. Typical electroporation rates can result in DNA transfection efficiencies of 2-5%, with cell viability of approximately 10-20%.

[0006] In a typical technique, electroporation is performed using two parallel plate electrodes, as shown in FIG. 1A. In this arrangement, cells typically flow between the two parallel plates. However, the electric field is non-uniform, and cells in the center of the chamber, as shown in (a), experience a more uniform electric field, while cells near the electrodes, as shown in (b), experience a non-uniform electric field, especially field action potentials that occur at the boundaries of the electrodes. Another technique utilizes parallel plates of micromesh electrodes, as shown in FIG. 1B (Non-Patent Document 3), in which cells pass through the upper and lower micromesh electrodes. While this technique provides a more uniform electric field than passing between two parallel electrode plates, as shown by the similar trajectories of cells in the center of the chamber (a) and near the boundaries of the chamber (b), the width of the chamber or the distance between the upper and lower micromesh electrodes is limited, resulting in low transfection efficiency. The arrangement shown in Figures 1A and 1B utilizes a field strength of approximately 1-1.3 kV / cm (eg, 200V / 2mm for parallel plates, 40V / 400um for parallel micromesh electrodes).

[0007] In another embodiment, single cell electroporation chip is used for transfection. In this technology, silicon chip may contain multiple linear channels, each channel has a counter electrode arranged on the opposite side of the channel. Cells pass through the channel and are exposed to an electric field. For this type of technology, about 68% DNA transfection efficiency has been achieved with about 79% cell survival rate. [Prior art document] [Patent documents] [Patent Document 1] U.S. Patent Application Publication No. 2017 / 0037357 [Non-patent literature] [Non-patent document 1] Leuk Res. (2009) 33:1255-9 [Non-Patent Document 2] Cytotherapy (2008) 10: 265-74 [Non-patent document 3] Selmeczi, D. et al., “Efficient large volume electroporation of dendritic cells through micrometer scale manipulation of flow in a disposable polymer chip,”Biomed Microdevices,13:383-392(2011) [Non-Patent Document 4] Moffett, et al., Nature Communications (2017) 8:389 [Summary of the Invention] [Problem to be solved by the invention] Although a variety of transfection systems and methods exist for mammalian cells, such techniques suffer from one or more disadvantages. Thus, there remains a need to provide improved electroporation systems and methods, particularly for high-throughput large-scale manufacturing processes. [Means for solving the problem] The technology presented herein is directed to various devices, systems, and methods for electroporation of cells, e.g., mammalian and non-mammalian cells, e.g., for large-scale continuous manufacturing processes. In particular, systems and methods for electroporation of cells using an electroporation apparatus that includes a first input separated by an offset distance from a first output can provide high efficiency and viability.

[0008] In some embodiments, a method of electroporating a cargo into cells is provided. The method includes flowing the cells with the cargo into an electroporation chamber. The electroporation chamber includes a first electrode, a second electrode, a first input that allows the passage of the cells and cargo into the electroporation chamber, a first output that allows the passage of the electroporated cells out of the electroporation chamber, and a fluid channel region having a path defined therein between the first and second electrodes for the cells and cargo to flow. Additionally, the cells are suspended in an electroporation medium and are about 1×10 6 Cells / ml ~ approx. 500 x 10 6 The method may have a cell density of about 100 cells / ml. The method further includes applying a plurality of electric pulses to the cells in the electroporation chamber, where (i) each electric pulse has an exponential ejection waveform or a square waveform, (ii) the plurality of electric pulses are applied at a field strength of about 0.3 kV / cm to about 3 kV / cm; (iii) the field strength is applied at a voltage of about 15 V to about 100 V; (iv) the duration between each electric pulse is about 0.1 seconds to about 10 seconds; and (v) each electric pulse has a pulse width of about 10 μs to about 10,000 μs.

[0009] In another aspect, an apparatus for electroporating a cargo into a cell is provided, the apparatus comprising one or more electroporation chambers, each of which comprises a first electrode, a second electrode, a first input for allowing passage of cells and cargo into the electroporation chamber, a first output for allowing passage of electroporated cells out of the electroporation chamber, and a fluid channel region having a path defined therein between the first and second electrodes for the flow of cells and cargo.

[0010] In another aspect, a kit for cell transfection is provided, the kit comprising an apparatus for electroporation as described herein, a first container for containing cells to be transfected and cargo, a second container for containing electroporated cells, tubing for fluidly connecting the first container and the second container to an apparatus for electroporating cells, and optionally reagents, such as cells to be transfected, electroporation medium, or a combination thereof.

[0011] Various objects, features, aspects and advantages of the subject matter described herein will become more apparent from the following detailed description of preferred embodiments, taken in conjunction with the accompanying drawings, in which numerals represent the components. [Brief description of the drawings] [FIGS. 1A-1B] Show a typical electroporation apparatus that includes parallel plate electrodes (as shown in FIG. 1A) and a micromesh electrode with no offset between the input and output (as shown in FIG. 1B).

[0012] [FIGS. 2A-2B] Show aspects of an apparatus for electroporation according to some embodiments provided herein.

[0013] [FIG. 2C] An embodiment of a first electrode and a second electrode according to some embodiments provided herein.

[0014] [Figure 2D] Block diagram of an apparatus for generating and providing electrical pulses to cells within an electroporation device as described herein, according to some embodiments provided herein.

[0015] [Figure 2E] Block diagram of a further apparatus for generating and providing an electrical pulse to cells within an electroporation apparatus as described herein according to some embodiments provided herein.

[0016] [FIGS. 3A-3D] Aspects of an apparatus for electroporation including an electroporation device according to some embodiments provided herein. FIG. 3A shows a diagram of the structure of an input-output chamber offset electroporation device. FIG. 3B shows a diagram of the electric field of an input-output chamber offset electroporation device. FIG. 3C shows the electric field strength as a function of cell migration distance through an input-output chamber offset electroporation device. FIG. 3D shows an alternative configuration of an electroporation device according to some embodiments provided herein.

[0017] [FIGS. 3E-3G] Show aspects of pathways within an electroporation chamber according to some embodiments provided herein.

[0018] [FIGS. 3H-3J] Show alternative configurations of an electroporation apparatus according to some embodiments provided herein.

[0019] [FIGS. 3K-3L] Illustrate example microfluidic chambers for sorting cells, according to some embodiments provided herein.

[0020] [Figures 3M-3S] Drawings showing various aspects of post geometry and positioning within a microfluidic chamber according to some embodiments provided herein.

[0021] [FIG. 3T] Illustrates an example microfluidic chamber for changing buffer solutions, according to some embodiments provided herein.

[0022] [FIG. 3U] Illustrates an example microfluidic chamber having two separate chambers, one for cell sorting and another for buffer change, according to some embodiments provided herein.

[0023] [Figures 3V-3W] Show alternative configurations of an electroporation apparatus according to some embodiments provided herein.

[0024] [Figure 3X] Shows the modular arrangement of an electroporation system including an electroporation apparatus according to some embodiments provided herein.

[0025]

[0023] FIG. 4 shows a table of parameters associated with a chamber offset electroporation apparatus, according to some embodiments provided herein.

[0026]

[0023] FIG. 5 shows examples of fluid flow waveforms (pumps) and electrical waveforms (stimuli) that may be applied to cells flowing through a chamber offset electroporation apparatus according to some embodiments provided herein.

[0027]

[0023] FIG. 6 illustrates various examples of micromeshes formed of different materials suitable for use in a chamber offset electroporation apparatus, according to some embodiments provided herein.

[0028] [Figures 7A-7E] Shows the results of electroporation experiments on haNK cells and corresponding parameters using the methods and devices described herein.

[0029] [Figures 8A-8D] Further results of electroporation experiments on haNK cells and corresponding parameters using the methods and devices described herein.

[0030] [FIGS. 9A-9D] Shows the results of electroporation experiments on EC7 cells and corresponding parameters using the methods and devices described herein.

[0031] [Figures 10A-10E] Show further results of electroporation experiments on EC7 cells and corresponding parameters using the methods and devices described herein.

[0032] [Figures 11A-11C] Show microscopic images of electroporated EC7 cells.

[0033] [Figures 12A-12B] Further results of transfected EC7 cells using the methods and devices described herein.

[0034] [Figures 13A-13D] Shows various transfection efficiencies in different cell lines using the methods and devices described herein.

[0035] [Figures 14A-14E] Show the results of transfection experiments to introduce mRNA into T cells using PbAE as described herein.

[0036] [Figures 15A-15B] Shown are the results of transfection experiments to introduce mRNA into T cells in the presence and absence of electroporation, as described herein.

[0037] [Figures 16A-16D] Shows the results of transfection experiments in adipose-derived mesenchymal stem cells (AD-MSCs) and corresponding parameters using the methods and devices described herein. [Mode for carrying out the invention] Systems and methods for electroporation of cells, such as mammalian cells (e.g., NK cells, EC-7 cells, T cells, etc.) and non-mammalian cells, are provided along with corresponding electroporation protocols that provide high efficiency and viability. In some embodiments, the electroporation protocols include subjecting the cells to multiple electrical pulses, graded fluid flow, electroporation buffers of low conductivity and low osmolality, relatively moderate volumes, and / or relatively moderate time constants.

[0038] In various aspects, a device for electroporating a cargo into a mammalian cell is provided. The device may include one or more electroporation chambers, where each electroporation chamber includes a first electrode, a second electrode, and a fluid channel region having a path defined therein between the first electrode and the second electrode. Each of the first and second electrodes may be a solid electrode or a mesh electrode, such as a micromesh electrode. The device also includes a first input that allows the passage of cells and cargo into the electroporation chamber, and a first output that allows the passage of electroporated cells out of the electroporation chamber. As used herein, "electroporated cells" includes transfected cells, dead cells, and non-transfected cells. In some embodiments, the first input and the first output may be separated by an offset distance. The first electrode may be surrounded by a first material and the second electrode may be surrounded by a second material, which may be the same or different.

[0039] For example, FIG. 2A illustrates an exemplary apparatus for electroporating a cargo into cells, including an electroporation apparatus 700a. The electroporation apparatus 700a includes an electroporation chamber 720 including two electrodes, e.g., a first electrode 740(1) and a second electrode 740(2), shown here in line with one another. The electroporation apparatus 700a further includes a first input 710 that allows passage of cells and cargo into the electroporation chamber 720 and a first output 730 that allows passage of electroporated cells from the electroporation chamber 720. The first input 710 and the first output 730 may be separated by an offset distance (d) to facilitate lateral flow of cells through the electroporation chamber 720. A fluid channel region 725 resides within the electroporation chamber 720, the fluid channel region 725 including a pathway 735 defined therein between the first electrode 740(1) and the second electrode 740(2) for the flow of cells and cargo. Although not shown, pathway 735 may have a pathway inlet corresponding to a first input for allowing passage of cells and cargo into pathway 735, and a pathway outlet corresponding to a first output 730 for allowing passage of electroporated cells from pathway 735.

[0040] In any embodiment, the first input may be present or defined at the first electrode, the second electrode, or the fluid channel region. Additionally, the first output may be present or defined at the first electrode, the second electrode, or the fluid channel region. Both the first input and the first output may be present at either the first electrode or the second electrode. For example, as shown in FIG. 2A, both the first input 710 and the first output 730 are present at the second electrode 740(2). Alternatively, the first input may be present at the first electrode and the first output may be present at the second electrode, or the first input may be present at the second electrode and the first output may be present at the first electrode. It is contemplated herein that in the case of a fluid channel region, the first input, the first output, or both may be present at, for example, a sidewall of the fluid channel region.

[0041] As further illustrated in FIG. 2B, in electroporation apparatus 700b, upper surface 706 of first electrode 740(1) may be surrounded by or connected to a first material 715(1) and lower surface 711 of second electrode 740(2) may be surrounded by or connected to a second material 715(2). For example, the first and second materials may be non-porous materials such as, for example, polydimethylsiloxane (PDMS) acrylic, polyethylene, polypropylene, or acrylic glass to contain cells within the interior chamber of the electroporation apparatus, particularly within the electroporation chamber between the parallel first and second electrodes. Additionally or alternatively, electroporation apparatus 700b may further include a first external input 750 to further enable passage of cells and cargo into electroporation chamber 720, and a first external output 760 to further enable passage of electroporated cells from electroporation chamber 720. The first external input may be present or defined in a first material, and the first external output may be present or defined in a second material. Alternatively, the first external input may be present or defined in a second material, and the first external output may be present or defined in a first material. In further embodiments, both the first external input and the first external output may be present or defined in a first material or a second material. For example, as illustrated in FIG. 2B, both the first external input 750 and the first external output 760 are present or defined in a second material 715(2), with arrows indicating the flow direction of cells and cargo through the electroporation device and electroporated cells exiting the electroporation device. Other openings or holes shown in FIG. 2A and FIG. 2B, and not numbered, represent openings for connecting various components of the electroporation device, for example, via screws and / or plugs, as known by those skilled in the art.

[0042] Each of the first and second electrodes may be a solid electrode, e.g., a solid plate electrode, or a mesh electrode having porosity, e.g., a micromesh electrode. In one embodiment, both the first and second electrodes are solid electrodes, e.g., solid plate electrodes. In any embodiment, when the first electrode, the second electrode, or both are solid electrodes, the first electrode, the second electrode, or both include a plurality or series of solid metal plates. For example, as illustrated in FIG. 2C, the first electrode 741(1) and the second electrode (741)(2) include a plurality of solid metal plates 745. Each solid metal plate 745 may be formed to apply an independent electric field to create a particular electric field pattern. Suitable materials from which the first and second electrodes may be formed include, but are not limited to, stainless steel, polyimide, silicon, precious metals, Group 4 metals, conductive materials, and combinations thereof. Examples of suitable noble metals include, but are not limited to, ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), osmium (Os), iridium (Ir), platinum (Pt), and gold (Au). Examples of Group 4 metals include titanium (Ti), zirconium (Zr), hafnium (Hf), and rutherfordium (Rf). Examples of suitable conductive materials include, but are not limited to, indium tin oxide (ITO), carbon nanotubes (CNT), and conductive polymers such as poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS).

[0043] In any embodiment, any one of the electroporation devices disclosed herein may include components for providing an electrical pulse to cells during an electroporation process with electroporation parameters as described herein. For example, FIG. 2D illustrates an apparatus 852 for generating and providing an electrical pulse to cells as described herein. Specifically, as shown in FIG. 2D, the apparatus 852 includes a power supply 854 and a control circuit 858 coupled to the power supply 854. The power supply 854 provides the electrical pulse to an electroporation apparatus 860 (e.g., any one of the example electroporation apparatuses disclosed herein).

[0044] In the example of FIG. 2D , the power supply 854 includes a power source 856, a power converter 862 coupled to the power source 856, and a pulse circuit 864 coupled between the power converter 862 and the electroporation device 860. The power converter 862 may include DC-DC power conversion circuitry and / or AC-DC power conversion circuitry, depending on, for example, the type of power provided by the power source 856. For example, the power converter 862 may receive DC power from the power source 856 (e.g., one or more batteries) and output a regulated DC voltage to the pulse circuit 864. In such an example, the power converter 862 may include a DC-DC power conversion circuitry (e.g., buck, boost, etc.) having any suitable conversion topology. In other examples, the power converter 862 may receive AC power from the power source 856 (e.g., AC mains). In such an example, the power converter 862 may include an AC-DC power conversion circuitry (e.g., AC-DC rectifier, PFC boost, etc.) having any suitable conversion topology.

[0045] 2D receives a DC voltage from power converter 862 and converts the DC voltage into DC electrical pulses for electroporation device 860. For example, pulse circuit 864 may include one or more switching elements (not shown) to read the DC voltage from power converter 862 and generate electrical pulses. In other examples, pulse circuit 864 may include other suitable circuitry for generating electrical pulses for electroporation device 860.

[0046] 2D , the control circuit 858 includes a controller 866 and a pulse generator 868 coupled to the controller 866. The controller 866 receives a feedback signal 870 representative of an output parameter (e.g., output voltage) of the power converter 862 and generates one or more control signals 872 for the power converter 862 to control one or more switching elements (not shown) within the power converter 862 based on the feedback signal 870. For example, the controller 866 may control the switching elements of the power converter to regulate the output voltage of the power converter to a specified value (e.g., a desired amplitude of an electrical pulse). In some examples, the controller 866 may decrease or increase the output voltage based on the feedback signal 870 and / or other signals disclosed herein.

[0047] 2D , the controller 866 may generate a signal 874 for the pulse generator 868, which may generate one or more control signals 876 for the pulse circuit 864 to generate electrical pulses based on the signal received from the controller 866. For example, the signal 874 may be a start and / or stop signal that instructs the pulse generator 868 to begin generating electrical pulses. In some examples, the pulse generator 868 may adjust the frequency, pulse width, duty cycle, etc. of the electrical pulses based on the signal received from the controller 866.

[0048] In some examples, control circuitry 858 may receive one or more additional signals for controlling power converter 862 and / or pulse generator 868. For example, and as shown in FIG. 2D, pulse generator 868 in control circuitry 858 may optionally receive one or more signals 878a. Signal 878a may be a feedback signal from pulse circuitry 864, electroporation device 860, etc., and may be used to control pulse circuitry 864 to generate electrical pulses. In addition, and as shown in FIG. 2D, controller 866 in control circuitry 858 may optionally receive one or more signals 880 representing feedback signals from pulse circuitry 864, electroporation device 860, etc., and / or one or more signals 882 representing user-defined commands from a user interface. In such examples, signals 880 and / or signals 882 may be used to control pulse circuitry 864 and / or power converter 862, monitor pulse timing, etc. In some examples, the device 852 may include one or more detectors (not shown) for monitoring a tip voltage and / or a tip current associated with the electroporation device 860. In such examples, the pulse generator 868 and / or the controller 866 may receive the sensed tip voltage and / or the sensed tip current via signals 878a, 880 and then control the pulse circuitry 864 and / or the power conversion device 862 based on the sensed tip voltage and / or current.

[0049] The control circuitry 858 may also generate one or more additional signals for control purposes. For example, the controller 866 may optionally generate one or more signals 884 for other components of the electroporation apparatus and / or components external to the electroporation apparatus. In such examples, the signals 884 may represent user feedback provided to a user interface, control signals for controlling motors (e.g., stepper motors) of liquid pumps, peristaltic pumps, pinch valves within the apparatus, and the like. In addition, the pulse circuitry 864 may optionally generate one or more signals 878b for other components of the electroporation apparatus and / or components external to the electroporation apparatus. For example, the pulse circuitry may generate a signal 878b for a detector to instruct the detector to begin monitoring voltage and current.

[0050] FIG. 2E illustrates another example apparatus 886 for generating and providing electrical pulses to cells as described herein. As shown, the apparatus 886 includes a power supply 888 coupled to an electroporation apparatus 860 and a control circuit 890 for controlling the power supply 888. The power supply 888 and control circuit 890 of FIG. 2E are similar to the power supply 854 and control circuit 858 of FIG. 2D, but include additional components. For example, the power supply 888 includes a filter 892 coupled between the power supply 856 and the power converter 862, as well as the power supply 856, power converter 862, and pulse circuit 864 of FIG. 2D. The filter 892 may include one or more components (not shown), such as a capacitor, inductor, etc., for smoothing the electrical signal from the power supply 856.

[0051] Additionally, and as shown in FIG. 2E, the control circuit 890 includes one or more gate drivers 894 coupled to the pulse generator 868 along with the controller 866 and pulse generator 868 of FIG. 2D. In the example of FIG. 2E, the gate driver 894 receives a signal from the pulse generator 868 and generates one or more pulse-width modulated (PWM) control signals 896 for controlling one or more switching elements (e.g., MOSFETs) in the pulse circuit 864. Additionally, the control circuit 890 may receive and / or generate any one or more of the various signals referenced in FIG. 2D. For example, the controller 866 may receive a feedback signal 870 and generate a control signal 872 for controlling one or more switching elements (e.g., MOSFETs) in the power converter 862 as described above.

[0052] The control circuitry disclosed herein may include hardware components and / or programmed software components for performing various functions, including those disclosed herein. For example, any one of the control circuits 858, 890 of Figures 2D and 2E may include one or more sensors for monitoring parameters of the power supply 854, 888 (described herein), parameters associated with the electroporation device 860, etc. The parameters may include electrical parameters associated with the power supply 854, 888 and / or the electroporation device 860, fluid parameters associated with the electroporation device 860, etc. In such examples, the control circuitry 858, 890 may control the power supply 854, 888 and / or other components of the device 852, 886 (e.g., liquid pumps, etc.) based on the parameters. It is contemplated herein that any one of the power supplies 854, 888 and any one of the control circuits 858, 890 described herein may provide electrical pulses and electroporation parameters as further described below, such as waveform, field strength, voltage, duration between each electrical pulse, pulse width, duration of each electrical pulse, etc. For example, any one of the control circuits 858, 890 may provide one or more of the following: (i) each electrical pulse has the form of an exponential ejection waveform or a square waveform; (ii) the multiple electrical pulses are applied at a field strength of about 0.3 kV / cm to about 3 kV / cm; (iii) the field strength is applied at a voltage of about 15 V to about 100 V; (iv) the duration between each electrical pulse is about 0.1 seconds to about 10 seconds; and (v) each electrical pulse has a pulse width of about 10 μs to about 10,000 μs.

[0053] In some embodiments, the first electrode may be an upper micromesh electrode and the second electrode may be a lower micromesh electrode. In such embodiments, the electroporation chamber may include an upper micromesh electrode, a lower micromesh electrode, and a defined pathway between the upper and lower micromesh electrodes for cells and cargo to flow. Each of the upper and lower micromesh electrodes has a porosity, for example, to allow passage of cells through the micromesh electrodes either into or out of the electroporation chamber. For example, each of the upper and lower micromesh electrodes may have a porosity, such as an open area of ​​about 30% to about 50%. The width of the pore openings of the upper and lower micromesh electrodes may be about 70 μm to about 140 μm. The upper micromesh electrode may be surrounded by a first material and the lower micromesh electrode may be surrounded by a second material. The first material includes a first input that allows passage of cells into the electroporation chamber and the second material includes a first output that allows passage of electroporated cells out of the electroporation chamber. Additionally or alternatively, rather than the cells and / or cargo migrating through the pores of the upper micromesh electrode and entering the electroporation chamber, the upper micromesh electrode may optionally include a second input for allowing passage of the cells and / or cargo into the electroporation chamber. The second input may be substantially aligned with the first input in the first material. Additionally or alternatively, rather than the electroporated cells migrating through the pores of the lower micromesh electrode and exiting the electroporation chamber, the lower micromesh electrode may include a second output for allowing passage of the electroporated cells out of the electroporation chamber. The second output may be substantially aligned with the first output in the second material.

[0054] For example, FIG. 3A illustrates an exemplary apparatus for electroporating a cargo into cells, which includes an IOCO electroporation apparatus 200 that includes micromesh electrodes. The IOCO electroporation apparatus 200 includes two micromesh electrodes, shown here aligned with one another, an upper micromesh electrode 240(1) and a lower micromesh electrode 240(2). The upper surface of the upper micromesh electrode 240(1) may be surrounded by a first material, and the lower surface of the lower micromesh electrode 240(2) may be surrounded by a second material. For example, the first and second materials may be non-porous materials, such as, for example, polydimethylsiloxane (PDMS), acrylic, polyethylene, polypropylene, etc., to contain cells within the interior chamber of the electroporation apparatus, particularly within the chamber 220 between the two parallel micromesh electrodes. The first input 210 is formed on the upper micromesh electrode 240(1) (area without PDMS) and the first output 230 is formed on the lower micromesh electrode 240(2) (area without PDMS). Thus, in this example, the upper micromesh electrode 240(1) and the lower micromesh electrode 240(2) span the length of the electroporation chamber 220 bounded by the first material (upper PDMS layer) and the second material (lower PDMS layer) to direct the flow of cells along the lateral distance of the chamber. The opening (first input 210) in the first material (upper PDMS layer) and the opening (first output 230) in the second material (lower PDMS layer) are separated by an offset distance (d) to facilitate the flow of cells through the lateral passage of the electroporation chamber 220.

[0055] In any embodiment, the electroporation chamber as described above may have any desired shape, including but not limited to circular, oval, square, rectangular, or polygonal.

[0056] In any embodiment, the electroporation chamber width (w) may be in the range of about 0.01 mm to about 15 mm, 0.01 mm to about 10 mm, 0.01 mm to about 7.5 mm, 0.01 mm to about 5 mm, about 0.05 mm to about 5 mm, about 0.1 mm to about 15 mm, 0.1 mm to about 10 mm, 0.1 mm to about 7.5 mm, about 0.1 mm to about 5 mm, about 1 mm to about 15 mm, about 1 mm to about 10 mm, about 1 mm to about 7.5 mm, about 1 mm to about 5 mm, about 2 mm to about 10 mm, about 2 mm to about 5 mm, about 0.01 mm to about 4 mm, about 0.1 mm to about 4 mm, about 1 mm to about 4 mm, about 0.01 mm to about 2 mm, about 0.05 mm to about 1 mm, about 0.1 mm to about 0.5 mm, or about 0.2 mm to about 0.4 mm. In some embodiments, the chamber width (w) is about 0.3 mm or about 4 mm.

[0057] In some embodiments, the offset distance (d) between the first input and the first output may range from about 0.1 cm to about 10 cm, about 0.1 cm to about 5 cm, about 0.1 cm to about 4 cm, about 1 cm to about 3 cm. In some embodiments, the offset distance (d) is about 2 cm. In some embodiments, there is no overlap between the input and the output.

[0058] The first input and / or the second input are in fluid communication with an electroporation chamber, and the electroporation chamber is in fluid communication with the first output and / or the second output. The inputs, outputs, and electroporation chamber may additionally include one or more valves, regulators, pumps, or any other microfluidic components to control the flow of cells through the electroporation chamber.

[0059] In some embodiments, both the first input and the first output may be located on a first material on the upper micromesh electrode, provided that a suitable offset distance is maintained between the first input and the first output. Additionally or alternatively, both the second input and the second output may be present on the upper micromesh electrode. In other embodiments, both the first input and the first output may be located on a second material on the lower micromesh electrode, provided that a suitable offset distance is maintained between the first input and the first output. Additionally or alternatively, both the second input and the second output may be present on the lower micromesh electrode.

[0060] In some embodiments, cells may enter a first input and flow in a first direction. Once past the first or second electrode, the stream of cells may change direction and flow laterally in a path along the length of the electroporation chamber in a direction perpendicular or substantially perpendicular to the first direction. Once at the first output, the stream of cells may change direction again and exit the electroporation chamber in a second direction parallel to the first direction.

[0061] In some embodiments, a voltage suitable for generating an electric field in the range of about 0.3 kV / cm to about 3 kV / cm is applied between the parallel first and second electrodes. Typical electric fields range from about 1 to 1.3 kV / cm (e.g., 40V / 300um) for haNKS cells and about 0.3 to 1 kV / cm for EC-7 cells. In some embodiments, the voltage may be about 10V, about 20V, about 30V, about 40V, about 50V, about 75V, about 100V, or about 200V, or any suitable range therein, or more.

[0062] In some embodiments, the diameters of the first input, the second input, the first output, and the second output may be approximately the same. In other embodiments, the diameter of the first input may be larger or smaller than the diameter of the first output, and / or the diameter of the second input may be larger or smaller than the diameter of the second output. For example, the diameter of the first input and / or the diameter of the second input may be in the range of about 0.1 mm to about 10 mm, about 1 mm to about 7 mm, about 3 mm to about 5 mm, or about 4 mm. The diameter of the first output and / or the diameter of the second output may be in the range of about 0.1 mm to about 10 mm, about 1 mm to about 7 mm, about 3 mm to about 5 mm, or about 4 mm.

[0063] In any embodiment, the length (l) of the electroporation chamber may be in the range of about 2 mm to about 100 mm, about 2 mm to about 80 mm, about 2 mm to about 60 mm, about 2 mm to about 40 mm, about 2 mm to about 20 mm, about 5 mm to about 100 mm, about 5 mm to about 80 mm, about 5 mm to about 60 mm, about 5 mm to about 40 mm, about 5 mm to about 20 mm, about 5 mm to about 15 mm, about 8 mm to about 12 mm, or may be about 10 mm.

[0064] In any embodiment, the height (h) of the electroporation chamber may range from about 100 μm to about 1000 μm, about 100 μm to about 750 μm, about 100 μm to about 500 μm, about 100 μm to about 300 μm, about 100 μm to about 200 μm, about 200 μm to about 1000 μm, about 200 μm to about 750 μm, about 200 μm to about 500 μm, or about 200 μm to about 300 μm. In some embodiments, the chamber height (h) is about 284 μm.

[0065] In any embodiment, the ratio of length (l) to width (w) (l / w) can be from about 1 to about 50, from about 1 to about 40, from about 1 to about 20, or from about 1 to about 10.

[0066] In any embodiment, once the cells enter the electroporation chamber, they are exposed to a uniform electric field until they exit the electroporation chamber. For example, Figure 3B is a diagram of the electric field in an IOCO electroporation apparatus 200. Position (1) refers to the cell at the input (first input 210), position (2) refers to the cell in the electroporation chamber, and position (3) refers to the cell at the output (first output 230).

[0067] 3C is a plot of electric field strength versus cell migration distance through the IOCO electroporation apparatus 200. Cells at the input (first input 210), designated position (1), are not exposed to the electric field until they pass through the micromesh electrode and enter the electroporation chamber. Within the electroporation chamber, designated position (2), the cells experience a uniform (full strength) electric field while migrating along the length of the chamber. Once at the output (first output 230), designated position (3), the cells are not exposed to the electric field.

[0068] 3D shows an alternative arrangement of electroporation devices as presented herein, including electroporation devices 310-330. In this embodiment, rather than having a straight (horizontal) flow path between the upper and lower meshes, the cells may take a curved or circular (horizontal) flow path between the upper and lower meshes. Each of the straight and curved flow paths may include at least one segment that extends parallel to a plane defined by at least one surface of the upper and lower meshes.

[0069] In this example, the various layers 310-330 of the electroporation device are shown in FIG. 3D. Solid outer plates 310(1) and 310(2) (e.g., plastic, metal, or any other suitable material) surround the device. An adhesive layer or other suitable material (e.g., double-sided tape, pressure-sensitive adhesive material, etc.) 320(1) (first material) is provided between the upper solid outer plate 310(1) and the upper mesh 330(1), and an adhesive layer or other suitable material (e.g., double-sided tape, pressure-sensitive adhesive layer, etc.) 320(2) (second material) is provided between the lower outer plate 310(2) and the lower mesh 330(2). Another adhesive layer (e.g., pressure-sensitive adhesive material or double-sided tape, etc.) (340) including a curvilinear channel or pathway 335 through which cells and cargo may flow is positioned between the upper mesh 330(1) and the lower mesh 330(2). Fluid may be driven through the electroporation devices 310-330 by a syringe 350. The electroporation devices 310-330 may also face an electroporator pulser 360. In any embodiment, the electroporation devices 310-330 may be a continuous electroporation device, where cells are flowed through the device in a continuous manner.

[0070] A pathway for cells and cargo to flow through the electroporation chamber is defined within the electroporation chamber, for example, within a fluid channel region as described above between a first electrode (e.g., a solid electrode or an upper micromesh electrode) and a second electrode (e.g., a solid electrode or a lower micromesh electrode). It is understood that any suitable pathway is contemplated by the embodiments provided herein, provided that it includes at least one horizontal flow segment that is parallel to at least one of the first electrode (e.g., a solid electrode or an upper micromesh electrode) and the second electrode (e.g., a solid electrode or a lower micromesh electrode). The horizontal flow segment may be formed to be longer or shorter than any of 1 / 10, 1 / 4, 1 / 2, 3 / 4, 7 / 8, or 9 / 10 of the length of the pathway extending between the upper and lower micromesh electrodes. In some cases, the pathway may be straight, curved, branched, circuitous, serpentine, or any combination thereof. Examples of curved pathways include, but are not limited to, circular pathways, helical pathways, conical pathways, or any combination thereof. For example, as illustrated in FIG. 3B, when the arrows illustrate the flow of cells, the path is linear. As illustrated in FIGS. 2A, 2B, 3D, and 3E, when the arrows illustrate the flow of cells, the path is curved. As illustrated in FIG. 3F, when the arrows illustrate the flow of cells, the path may be linear with one or more changes in direction or switchbacks. As illustrated in FIG. 3G, the path may be circular and have one or more branches. As illustrated in FIGS. 3E-3G, the path may include an inlet 380 (out of plane) that may correspond to or be substantially aligned with the first input, and one or more outlets 390 (in plane) that may correspond to or be substantially aligned with the first output. The length of the path may be adjusted, e.g., shortened or lengthened, depending on the particular characteristics of the electroporation process.

[0071] In any embodiment, the electroporation device described herein may include a means for generating a flow of cells from a sample tube to the electroporation chamber of the electroporation device, through the device, and into a collection tube. For example, as illustrated in FIG. 3H, a flow generating means 520 is in fluid communication, e.g., via tubing, with a sample tube 510 containing cells and / or cargo to be transfected and an electroporation device 530. The flow generating means 520 may generate a flow of cells and / or cargo from the sample tube 510, through the tubing, through the electroporation device 530, and into the collection tube 550. Although not illustrated, an air filter device may be in fluid communication with the contents of the sample tube 510, the collection tube 550, or both. The flow generating means may be any suitable pump, e.g., a peristaltic pump or a syringe pump. It is contemplated herein that more than one flow generating means 520 may be present in an electroporation device. For example, one or more flow generating means 520 may be in fluid communication between the sample tube 510 and the electroporation device 530, and one or more flow generating means 520 may be in fluid communication between the collection tube 550 and the electroporation device 530. Additionally or alternatively, the electroporation device 530 and / or the flow generating means 520 may also interface with a controller 540, which may include, for example, an electroporator pulser.

[0072] In any embodiment, the electroporation device described herein may also include a priming buffer tube in fluid communication with the electroporation device for delivering a priming buffer as needed. Examples of suitable priming buffers include, but are not limited to, distilled water, deionized water, isotonic buffer, and combinations thereof. For example, as illustrated in FIG. 3I, priming buffer tube 560 is in fluid communication with electroporation device 530. Valve 570 may be opened to deliver priming buffer to electroporation device 530 via flow generating means 520, or valve 570 may be closed to stop delivery. Valve 575 may be opened to deliver cells and / or cargo to electroporation device 530 via flow generating means 520, or valve 575 may be closed to stop delivery. In some embodiments, both valves 570 and 757 may be opened to deliver cells and priming buffer. In some embodiments, priming buffer may be delivered first, followed by cells and / or cargo.

[0073] In any embodiment, the electroporation apparatus described herein may also include a first microfluidic device for sorting cells before they enter the electroporation chamber of the electroporation apparatus. For example, as illustrated in FIG. 3J, the first microfluidic device 580 may be in fluid communication with the electroporation apparatus 530, the sample tube 510 containing the cells to be transfected, and optionally the buffer sorting tube 577. The flow generating means 520 may generate a flow of cells from the sample tube 510 and / or buffer from the sorting tube 577 through the electroporation apparatus 530 and to the collection tube 550. The first microfluidic device 580 is capable of pre-sorting cells from the sample tube 510 to the electroporation apparatus 530, for example based on the size of the cells. Additionally or alternatively, the first microfluidic device 580 is capable of effecting a buffer change of the cells from the sample tube 510. Stream 590 contains cells that have been sorted out and are not delivered to electroporation apparatus 530 and can either be a waste stream or can be delivered to another electroporation apparatus using different parameters. Additionally or alternatively, a second microfluidic device 585 can be in fluid communication with electroporation apparatus 530 and collection tube 550. Second microfluidic device 585 is capable of sorting electroporated cells prior to collection in collection tube 550, for example, based on the size of the electroporated cells. Stream 595 contains electroporated cells that have been sorted out and are not delivered to collection tube 550.

[0074] Although two microfluidic devices are shown in FIG. 3J, it is contemplated herein that only one microfluidic device may be present in the electroporation apparatus, for example, to sort cells prior to entering the electroporation chamber, or to sort electroporated cells exiting the electroporation chamber.

[0075] FIG. 3K is a diagram of an example microfluidic device (e.g., microfluidic device 580, microfluidic device 585). In this example, a solution containing cells 100 (e.g., cells to be transfected, electroporated cells, transfected cells) enters chamber 105 at input feature 110. The cells are illustrated as circles. The cells pass through chamber 105, which contains a matrix of posts 115, shown here as rectangular structures distributed along a number of lines with a gradient. As the cells pass between the diagonally oriented post rows in the chamber, they are deflected laterally towards second output feature 122. A side view of a portion of the chamber is shown in FIG. 3L, where the chamber has a floor 160 and optionally a ceiling 150, which may be made of the same material as posts 115 or a different material. Cells (black circles) are shown flowing through the matrix of posts. It is understood that the post rows may also be arranged in a curved fashion, resulting in cells being directed towards the sides of the chamber.

[0076] In this example, two output mechanisms are shown for the chamber. The solution exiting the chamber via the first output mechanism 120 (which may also be referred to as the third output mechanism when more than one microfluidic device is present) is depleted of cells, while the solution exiting the chamber via the second output mechanism 122 (which may also be referred to as the fourth output mechanism when more than one microfluidic device is present) is enriched in cells. In any embodiment, the second output mechanism may be in fluid communication with the electroporation chamber, for example with the first input. Depletion refers to a condition in which the concentration of cells in the solution exiting the chamber via the output mechanism 120 is reduced by 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% compared to the concentration of cells in the solution entering the chamber at the input mechanism 110. Enrichment or concentration refers to a condition in which the concentration of cells in the solution leaving the chamber via the output mechanism 122 is increased by 50%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000% or more compared to the concentration of cells in the solution entering the chamber at the input mechanism 110. For cells to be directed to the output mechanism 122, the deflection point 130 of the chamber must be positioned such that any cells present are directed to the output mechanism 122 (and not the output mechanism 120). In general, the output mechanism 122 is formed to have a larger cross-sectional area than the output mechanism 120. In general, the output mechanism has a cross-sectional area large enough for fluid flow at the flow rates described herein to not result in high pressures that would damage the cells or the device.

[0077] In some embodiments, the width of output feature 120 is greater than the width of output feature 122. For example, the width of output feature 120 is 1.5 times, 2 times, 2.5 times, 3 times, 3.5 times, 4 times, 4.5 times, 5 times, 5.5 times, 6 times, 6.5 times, 7 times, 7.5 times, 8 times, 8.5 times, 9 times, 9.5 times the width of output feature 122. In other embodiments, the sum of the cross-sectional areas of the output features may be greater than or equal to the sum of the cross-sectional areas of the input features.

[0078] In some embodiments, the microfluidic device is configured to allow connection to a microfluidic device such as a standard pump or syringe so that a solution containing cells can flow through the device. Parameters that can affect the flow of solution through the device include the dimensions of the chamber 105, the in-plane and out-of-plane dimensions of the posts 115, the spacing of the posts within a row (dx), the rotation of the posts (Φ), the distance between the rows of posts (dy), the diameter of the input feature, and the diameter of the output feature (see Figures 3M-Q below). In some embodiments, the dimensions of these parameters are selected to accommodate the applied pressure from the manual operation of a syringe or a standard pump (e.g., peristaltic pump, diaphragm pump, syringe pump, lobe pump, etc.) that drives the flow of the solution through the device. Various pressures are acceptable provided that the pressure does not damage the microfluidic device or the cells.

[0079] In general, cells may flow through the microfluidic device serially (one at a time in a particular pathway) or in multiples (with multiple cells flowing in multiple pathways).

[0080] 3M is a drawing of a top-down view of a cross section of chamber 105, where each cross section contains two rows of seven posts. The flow of cells is shown along a path (p). This drawing shows the positioning of posts 115 within the cross section of the chamber of the microfluidic device. In general, the posts are aligned along a line having a slope as defined by an angle (θ) at a spatial interval (dx), which may be fixed or variable, provided that the variation does not result in the avoidance of cells from the path (p) between the posts.

[0081] In some embodiments, the width of the chamber is 1 mm, 2.5 mm, 5 mm, 7.5 mm, 10 mm, 12.5 mm, 15 mm, 17.5 mm, 20 mm, 30 mm, 40 mm, 50 mm, or more, or any size therebetween. The width of each path (p) controls the characteristics of the flow line. For example, any number of paths may be utilized depending on the width of the chamber, such as 1, 2, 4, 8, 12, 16, 32, etc., or any range therebetween. In other embodiments, the flow rate of the fluid through the chamber may be 1 mL / hr, 2 mL / hr, 3 mL / hr, 4 mL / hr, 5 mL / hr, 6 mL / hr, 7 mL / hr, 8 mL / hr, 9 mL / hr, 10 mL / hr, 15 mL / hr, 20 mL / hr, 25 mL / hr, 30 mL / hr, 40 mL / hr, 50 mL / hr, etc. The chamber is desirably rectangular, but may also be circular, semicircular, V-shaped, or any other suitable shape.

[0082] The angle (θ) is the angle between the horizontal axis having zero slope and the line along which the posts are distributed with the slope (in this example the angle provides a measure of the negative slope (tan(θ)=Δy / Δx of the row of posts). Since in this example each row of posts is arranged on a diagonal, it is understood that the posts may have a positive or negative slope. It is understood that the diagonal may encompass any orientation that is not parallel or perpendicular to the chamber, for example, clockwise or counterclockwise, and angles between 1° and 89°, between 91° and 179°, between 181° and 269°, or between 271° and 359°. Other exemplary angle ranges may be 1° to 10°, 11° to 20°, 21° to 30°, 31° to 40°, 41° to 50°, 51° to 60°, 61° to 70°, 71° to 80°, 81° to 90°, 91° to 100°, 101° to 110°, 111° to 120°, 121° to 130°, 131° to 140°, 141° to 150°, 151° to 160°, 161° to 170°, or 171° to 180°.

[0083] Typically, multiple rows of posts are present in the chamber, with each row having the same or substantially the same slope as defined by the angle (θ). When cells 100 enter the chamber 105 of the microfluidic device, they flow laterally toward the side of the chamber 105, down multiple paths (p) between the posts 115 until they reach the side of the chamber. When concentrating cells, not only do they not typically cross the rows of posts, but they typically travel along a specific path (p). The cells then exit the microfluidic chamber via the output mechanism 122. In other embodiments, the posts may have curved components along the length of the chamber 105.

[0084] As used herein, the term "post" refers to a structure inside a chamber that has associated planar dimensions, out-of-plane dimensions, rotation angles, and shapes. In-plane dimensions may refer to the length (l) and width (w) of the post, while out-of-plane dimensions may refer to the height (h) of the post. Tilt or rotation angle (Φ) refers to the rotation of the post relative to the chamber.

[0085] Shape refers to the three-dimensional characterization of the post, e.g., cylindrical, conical, pyramidal, cubic, or cuboid. Generally, the post is positioned such that its axis (out-of-plane dimension) is perpendicular to the surface to which it is attached. In some embodiments, all posts within the chamber are of the same dimension. In other embodiments, the dimensions of the post vary as a function of space depending on the position, e.g., measured along the height (h) of the post. Generally, the post may be of any shape and is not limited to the specific geometric shapes presented herein. The post shape may be any shape, as shown in FIG. 3R, which is represented by a number of radii (r4-r12) associated with the bend, located, e.g., at repeating constant intervals or repeating variable intervals along the length of the axis, in addition to the length (l) and width (w) of the axis. Any number of different shapes may be described by the number of radii. Additionally, with reference to FIG. 3R and FIG. 3S, one or more sides of the post may be of a straight line shape. Thus, the post may have any suitable shape consisting of curves and / or straight lines.

[0086] In some embodiments, the posts are arranged at intervals (dx) along a gradient line, where the intervals are regularly spaced or fixed. For example, the posts may be positioned, for example, every 5 μm, 10 μm, 15 μm, 20 μm, 25 μm, 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 55 μm, 60 μm, 65 μm, 70 μm, 75 μm, 85 μm, 90 μm, 95 μm, 100 μm (including any value between these ranges) depending on the size of the cells to be enriched.

[0087] In other embodiments, the posts are distributed along a line with a gradient such that the spacing is not fixed but varies between any two consecutive posts. Any spacing (dx) is allowed, provided that it is small enough to prevent the cells from avoiding the path (p). For example, in the case of variable spacing, the first post may be placed at a specific location, the second post may be placed 5 μm from the first post, and the third post may be placed 4 um from the second post. The spacing may be selected based on the size of the cells.

[0088] In some embodiments, the spacing may be selected to be large enough to allow enrichment of certain types of cells while allowing smaller cells to exit via the output mechanism 120. For example, a blood sample may contain multiple different cell types of relatively small size, such as red blood cells, neutrophils (e.g., 12-14 μm diameter), eosinophils (e.g., 12-17 μm diameter), basophils (e.g., 14-16 μm diameter), lymphocytes (e.g., 10-14 μm diameter), and monocytes (e.g., 20 μm diameter). Other types of cells in the human body are much larger, e.g., in the range of 40-100 μm diameter or larger. In such cases, the posts may be spaced apart to allow passage of red blood cells and white blood cells while enriching larger cells (e.g., normal cells, tumor cells, etc.). The placement (spacing) of the posts is determined based on the type of cells being isolated. Different sheath flow to sample flow ratios may affect size-based sorting performance.

[0089] Each post has an associated length (l), also referred to as the in-plane dimension, a width (w), and a height (h), also referred to as the out-of-plane dimension (see also FIG. 3N). In some embodiments, the width of the post may be 5 μm, 10 μm, 15 μm, 20 μm, 25 μm, 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 55 μm, 60 μm, 65 μm, 70 μm, 75 μm, 85 μm, 90 μm, 95 μm, 100 μm, etc., or any value therebetween. The length of the posts may be 5 μm, 10 μm, 15 μm, 20 μm, 25 μm, 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 55 μm, 60 μm, 65 μm, 70 μm, 75 μm, 85 μm, 90 μm, 95 μm, 100 μm, etc., or any value therebetween. In general, the posts may be of any shape (in terms of top-down orientation and in relation to dimensions w and l), such as, but not limited to, circular, oval, square, rectangular, etc.

[0090] In the examples presented herein, the posts have an oval or rectangular shape. In some embodiments, the length of the post is 1.1 to 10 times greater than the width of the post; 1.1 to 5 times greater than the width of the post; 2 to 4 times greater than the width of the post; 3 to 4 times greater than the width of the post; or 2 to 3 times greater than the width of the post. In some embodiments, the length and width may have a ratio greater or less than 20 to 1, 18 to 1, 16 to 1, 14 to 1, 12 to 1, 10 to 1, 9 to 1, 8 to 1, 7 to 1, 6 to 1, 5 to 1, 4 to 1, 3 to 1, 2 to 1, 1.1 to 1, or any smaller or greater ratio.

[0091] In some embodiments, the cross-section of a post may be defined by the intersection of the post with a plane that is parallel to the original wall through which the post extends with height (h). The cross-section may be symmetric in either or both of the length (l) and width (w) directions.

[0092] In yet another embodiment, the length and width of each post in the matrix is ​​the same. In yet another embodiment, if the posts are circular, the radius of each post in the matrix is ​​the same.

[0093] Additional features include the rotation angle of the post (Φ), the height or out-of-plane dimension of the post, the spacing between rows (dy), and the offset of the rows (xo), which are described in more detail in Figures 3N-3Q and throughout the application. As used herein, the term "rotation angle" refers to the degree of rotation of the post relative to its position in the chamber. In some embodiments, the post has a length greater than its width. In this embodiment, a rotation angle of 0 means that the length of the post is aligned with an axis perpendicular to the side of the chamber. To describe different rotation angles, the post may be rotated in a clockwise or counterclockwise direction. As an example, the post in Figures 3M-Q is rotated approximately 35° in a counterclockwise motion to reach the post geometry shown in these figures.

[0094] 3N, each post has a height (h) or out-of-plane dimension associated with the post being sufficiently tall to prevent cells from escaping the path (p) by flowing in the upper path (e.g., over the top of the post into a different path). For example, in some embodiments, the post will span the height of the microfluidic chamber, such as being in contact with the chamber floor 160 and the chamber ceiling 150. In other embodiments, the height or out-of-plane dimension of the post may span a portion of the total height of the microfluidic device. For example, the post may have a height of 1 μm, 3 μm, 5 μm, 10 μm, 15 μm, 20 μm, 25 μm, 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 55 μm, 60 μm, 65 μm, 70 μm, 75 μm, 85 μm, 90 μm, 95 μm, 100 μm, etc., or any value therebetween.

[0095] Referring to Figure 3O, each post has an associated rotation angle (Φ) or tilt, as shown from a top-down view. In this example, the rotation of the post is determined based on an orientation such that the length of the post is aligned with a first axis perpendicular to the side of the chamber, and the width of the post is aligned with a second axis parallel to the side of the chamber, by rotating the post in a counterclockwise direction, for example about 35° counterclockwise in this example, until the desired rotation is reached. Any rotation angle that facilitates the passage of cells into the pathway (p) may be utilized, and all such rotation angles are contemplated herein. In some embodiments, the rotation angle is between 1° and 179°, between 1° and 89°, between 5° and 85°, between 10° and 80°, between 15° and 75°, between 20° and 70°, between 25° and 65°, between 30° and 60°, between 35° and 55°, between 40° and 50°, between 30° and 40°, between 32° and 38°, between 34° and 36°, or 35°. In other embodiments, the rotation angle may be between 91° and 179°, between 95° and 175°, between 100° and 170°, between 105° and 165°, between 110° and 160°, between 115° and 155°, between 120° and 150°, between 125° and 145°, between 130° and 140°, or 135°.

[0096] As shown above, the posts are distributed along a line with a negative slope. By directing the cells along this line, the cells flowing through path (p) are directed laterally towards the side of the chamber, while the solution in which the cells were initially suspended is allowed to flow in a manner (e.g., approximately horizontally or horizontally) and exit the microfluidic chamber via output mechanism 120.

[0097] 3P, in yet other embodiments, the rows of posts are spaced apart by a distance (dy). In some embodiments, the posts are arranged along a vertical line at a distance (dy), where the distance is regularly spaced or fixed. For example, the posts may be positioned every 5 μm, 10 μm, 15 μm, 20 μm, 25 μm, 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 55 μm, 60 μm, 65 μm, 70 μm, 75 μm, 85 μm, 90 μm, 95 μm, 100 μm, etc. (including any value therebetween) depending on the size of the cells to be enriched.

[0098] In other embodiments, the posts are distributed along a vertical line such that the spacing (dy) is not fixed, but instead varies between any two consecutive post rows. For example, a first post row may be located at a specific position, a second post row may be located 5 μm from the first post row, a third post row may be located 4 um from the second post row, and so on, aligned with respect to a vertical line. The spacing (dy) may be selected based on the size of the cells to be enriched. Any spacing (dy) is acceptable, provided that the spacing is wide enough to allow the flow of solutions into the chamber without requiring high pressures that may damage the microfluidic device. In some embodiments, consecutive post rows may have a zero offset (xo).

[0099] With reference to FIG. 3Q, successive post rows may have an offset (xo) relative to the spacing (dx). For example, row (r) may be fixed at a particular location (e.g., using a Cartesian coordinate system x,y). The (r+1)th row may be displaced to the right by an amount (xo). The (r+2)th row may be displaced to the right by an amount (2xo). The (r+3)th row may be displaced to the right by an amount (3xo), and so on, up to the spacing (dx). The offset may be provided in a fixed manner, such that each successive row is displaced in the same direction by a fixed amount. Alternatively, the offset may be provided in a variable manner, such that each successive row is displaced in the same direction by a variable amount (up to an amount of (dx)). In other embodiments, the offsets may be applied in alternating directions relative to columns (r), such that the (r+1)th column has a fixed or variable offset in one direction and the (r+2)th column has a fixed or variable offset in the opposite direction (e.g., one offset to the right and the next offset to the left).

[0100] The posts may be made of any suitable material, such as poly(dimethylsiloxane) (PDMS), glass, plastic, elastomers, silicon, etc. PDMS can generally be fabricated to have sub-micron resolution (e.g., features less than 0.1 μm). In some embodiments, the chamber 105 and / or the posts 115 may be made of PDMS. In other embodiments, the chamber may be fabricated of glass and / or silicon and / or plastic, and the posts may be fabricated with PDMS (e.g., the bottom of the chamber may be glass or silicon, and the top of the chamber may be glass or plastic). Lithography, as is well known in the art, may be utilized to fabricate the chambers and posts as described herein. Materials with similar properties to PDMS may also be used to construct the microfluidic devices shown herein.

[0101] Additionally, specific embodiments may include a number of additional features, including valves (e.g., between an input mechanism and a chamber, between a chamber and an output mechanism, between an output mechanism and another input mechanism or another chamber, etc.), pumps, and mixers. In some embodiments, valves may be placed in the PDMS during curation.

[0102] A variety of techniques are available for fabricating microfluidic devices. Microfluidic devices may be formed from one or more of the following materials: poly(methyl methacrylate) (PMMA), polycarbonate, polystyrene, polyethylene, polyolefins, silicones (e.g., poly(dimethylsiloxane) (PDMS)), silicon, and combinations thereof. Other materials are known in the art.

[0103] Methods for fabricating chambers and microfluidic devices having posts using the materials referenced herein are also known in the art and include, but are not limited to, embossing, laser micromachining, milling, molding (e.g., thermoplastic injection molding or compression molding), photolithography (e.g., stereolithography or x-ray photolithography), silicon micromachining, wet or dry chemical etching, and the like.

[0104] Silicon fabrication techniques using photolithography followed by wet (KOH) or dry etching (reactive ion etching with fluorine or other reactive gases) are available for glass materials. For example, a glass master can be formed by conventional photolithography to serve as a master mold in molding techniques to create plastic or PDMS based devices.

[0105] Microfluidic devices may be fabricated in one or more layers that are joined together, for example, by adhesives, clamps, heat, solvents, etc. Alternatively, the microfluidic device may be fabricated as a single piece, for example, using stereolithography or other three-dimensional manufacturing techniques.

[0106] In some embodiments, due to the deformability of the cells, the gap distance may be selected to be about 5 μm or less relative to the size (e.g., diameter) of the cells to be enriched. In other embodiments, the gap distance may be selected to be about 5 μm or more relative to the size (e.g., diameter) of the cells to be sorted. For rigid cells or microparticles having the same or similar diameter as the deformable cells, the gap distance may be different (e.g., larger for rigid cells) compared to the gap distance in deformable cells of the same diameter.

[0107] FIG. 3T is a diagram of another example microfluidic cell concentration device. In this example, a first solution containing cells 100 enters a chamber 105 at a first input feature 110. The cells are illustrated as circles. The cells pass through the chamber 105, which contains a matrix of posts 115, shown here as rectangular structures distributed along gradient lines. As the cells pass between the diagonally oriented rows of posts in the chamber, they are deflected laterally toward the sides of the chamber. As in FIG. 3L, the chamber has a floor 160 (not shown) and an optional ceiling 150, which may be of the same material as the posts 115 or a different material.

[0108] In this example, a second input mechanism 112 is present in the system. A second solution (e.g., a different buffer than the first solution entering the chamber through the first input mechanism 110), such as a buffer from buffer tube 577, enters the chamber through the second input mechanism 112. In some embodiments, the first and second solutions do not substantially mix, such that the upper region 155 of the chamber contains the first solution and has little, if any, of the second solution, while the lower region 165 of the chamber contains the second solution and has little, if any, of the first solution. Thus, when the cells are deflected laterally and exit the chamber through the output mechanism 122, the solution exiting the chamber through the output mechanism 122 is in a buffer of the second solution.

[0109] In some embodiments, buffer changes may be performed sequentially in a cascade design, as shown in FIG. 3U. In this example, a first solution containing cells 100 enters a first chamber 105(1) at a first input mechanism 110(1). The cells are illustrated as circles. The cells pass through a chamber 105(1), which contains a matrix of posts 115(1), shown here as rectangular structures distributed along a gradient line. As the cells pass between the diagonally oriented rows of posts in the chamber, they are deflected laterally. As in FIG. 3L, the chamber has a floor (160) (not shown) and an optional ceiling (150), which may be the same material as the posts 115 or a different material. The (concentrated) cells exit the chamber through an output 122(1) that flows to an input mechanism 110(2) if the second input mechanism 112 is the input of the system.

[0110] A second solution (e.g., a buffer solution) enters the chamber through a second input mechanism (112) distinct from the first solution, which enters the chamber through the first input mechanism 110(1). In some embodiments, the first and second solutions do not substantially mix, such that an upper region (155) of the chamber contains the first solution and has little, if any, of the second solution, while a lower region (165) of the chamber contains the second solution and has little, if any, of the first solution. The cells (concentrated and present in the buffer solution from the input mechanism 112) exit chamber 105(2) through output mechanism 122(2).

[0111] In other aspects, buffer changes may be performed in parallel. For example, the flow path may be divided so that the sample flows into multiple chambers, where each chamber includes an input for a buffer. In this arrangement, the same buffer may be provided to each of the parallel chambers, such that cells are concentrated in the same buffer. Alternatively, different buffers may be provided to each of the parallel chambers, such that cells are concentrated in different buffers, for example in different downstream assays.

[0112] In general, the input mechanism may be actuated by a syringe pump or by manual depression of a syringe. In some embodiments, multiple inputs may use one or more syringe pumps to automatically actuate each input. In other embodiments, multiple inputs may use manual depression of one or more syringes to manually actuate each input.

[0113] In any embodiment, electroporation devices capable of providing different electroporation effects are described herein. For example, as illustrated in FIG. 3V, an electroporation device 600 is provided having three electrodes 640(1), 640(2), 640(3). The electroporation device 600 includes two paths for cells and cargo to travel, a first path between electrodes 640(1) and 640(2) and a second path between electrodes 640(2) and 640(3), where the arrows indicate the flow of cells. Cells can enter the electroporation chamber at inlet 620 and exit via outlet 630. Although not illustrated, it is contemplated herein that there may be more than one outlet, e.g., each outlet may collect a different type of cell. Different electrode gap lengths (L1, L2, L3, L4) are present in the electroporation device 600. Different electrode gap lengths and different pathways result in different capacitances; therefore, different electric field strengths and electroporation effects can be achieved in cells moving in each pathway. For example, L2 can be made larger than L4, and in such an example, the capacitance (C1) in the first pathway can be made larger than the capacitance (C2) in the second pathway (C1>C2). In any embodiment, cells (same or different types) may be pre-sorted and / or selected, for example, using the microfluidic device described above, before entering the first pathway or the second pathway.

[0114] It is also contemplated herein that the electroporation devices described herein may exist as cartridges that may be in fluid communication (e.g., connected, stacked) with one another to provide a pathway of a desired length and shape. For example, as illustrated in FIG. 3W, each of the cartridges 410 includes an electroporation chamber that includes a first electrode 440(1) and a second electrode 440(2), where the cartridges may be stacked one on top of the other, with the arrows indicating the flow of cells through the cartridges. For example, the outlet of the top cartridge 410 is in fluid communication with the inlet of the middle cartridge 410, and the outlet of the middle cartridge 410 is in fluid communication with the inlet of the bottom cartridge 410.

[0115] In a further embodiment, a modular system is provided that includes the electroporation device described herein. For example, as illustrated in FIG. 3X, the modular system 800 includes three modules that are configured to be in fluid communication or connection with each other, such as a first module 805, a second module 815, and a third module 825. The first module 805 includes a first container 807 (e.g., a sample tube) for containing cells and / or cargo to be transfected, and a tube 810 for fluidly connecting the first container 807 with the second module 815. The first module 805 may also optionally include an air filter device 809 and a tube 810 for fluidly connecting the air filter device 809 to the first container 807. The second module 815 includes an electroporation device 820 and tubing 810 for fluidly connecting the electroporation device to the first module 805, e.g., the first container 807, and to a third module 825, as well as tubing 810 for fluidly connecting a flow generating means as described herein (e.g., a peristaltic pump) to the electroporation device 820 and to the first module 805, e.g., the first container 807. The third module 825 includes a second container 830 (e.g., a collection tube) for collecting electroporated cells, as well as tubing 810 for fluidly connecting the second container 830 to the second module 815, e.g., the electroporation device 820. The third module 825 may also optionally include an air filter device 809 and tubing 810 for fluidly connecting the air filter device 809 to the second container 830. Optionally, connectors 850, e.g., luer locks, may connect the modules together, e.g., first module 805 with second module 815 and second module 815 with third module 825. It is contemplated herein that each of first module 805, second module 815, and third module 825 may be packaged and sterilized separately.

[0116] The electroporation apparatus described herein has several advantages over mesh-based electroporation apparatus, such as the arrangement shown in Figure IB. First, the distance traveled through the electroporation chamber is increased as measured from the first input to the first output of the electroporation chamber, without a corresponding increase in the electric field. Thus, cells are exposed to a uniform electric field for a longer period of time than in a strictly straight flow path, resulting in improved electroporation efficiency without a corresponding decrease in viability.

[0117] The electroporation chamber width (w) between the upper and lower mesh electrodes may be increased in FIG. 1B, resulting in a longer travel distance, but the larger electroporation chamber width will have a larger impedance and a higher voltage will need to be applied to generate a suitable electric field. In addition, a higher voltage is more likely to have a detrimental effect on cell viability. Furthermore, in a parallel plate electrode configuration, such as in FIG. 1A, the electric field distribution is not uniform.

[0118] Thus, according to embodiments, the electroporation devices described herein can have shorter electrode pairs due to the offset input-output design, thereby extending the length of the electroporation chamber and not increasing the electrode pair distance.

[0119] 4 presents a table illustrating differences between the electroporation device as described herein and prior art electroporation devices, including, but not limited to, (1) the presence of an input-output offset distance, (2) the use of low conductance, low osmolality electroporation media instead of commercially available electroporation media such as BTX and RPMI, (3) an exponential ejection waveform applied in a series of electrical pulses, and (4) a staged fluid flow scheme.

[0120] While the examples in Figures 3A-3C utilize stainless steel micromesh electrodes, the electrodes are not limited to any particular material and may be formed of any suitable material. For example, as shown in Figure 6, suitable materials include silicon and polyimide. Although silicon and polyimide may be used to form suitable micromesh electrodes, such materials are typically processed in clean room facilities using microfabrication protocols known in the art. In contrast, stainless steel micromesh electrodes are easy to set up and do not require dedicated facilities, such as clean rooms.

[0121] It will be appreciated that any suitable material may be used, provided the micromesh has pores that allow the passage of cells (e.g., the micromesh pores are larger than the cells) and the micromesh pores are compatible with the electrode patterning around the pore openings.

[0122] Electroporation Methods and Parameters A method of electroporating a cargo into a cell is provided herein, along with an electroporation device, for example as described above. The method may include flowing the cells with the cargo into an electroporation chamber. The electroporation chamber includes a first electrode (e.g., a solid electrode), a second electrode (e.g., a solid electrode), and a fluid channel region having a path defined therein between the first electrode and the second electrode, all as described herein. The device also includes a first input that allows the passage of the cells and cargo into the electroporation chamber as described herein, and a first output that allows the passage of the electroporated cells out of the electroporation chamber as described herein. In some embodiments, the first input and the first output may be separated by an offset distance. The cells may be suspended in an electroporation medium. The first electrode may be surrounded by a first material as described herein, and the second electrode may be surrounded by a second material as described herein, which may be the same or different. The first material and the second material may also include a first external input as described herein, and a first external output as described herein.

[0123] In some embodiments, the electroporation chamber includes an upper micromesh electrode as described herein, a lower micromesh electrode as described herein, and a defined pathway between the upper and lower micromesh electrodes for the flow of cells and cargo as described herein. Each of the upper and lower micromesh electrodes has a porosity as described herein. In addition, the upper micromesh electrode may be surrounded by a first material as described herein. The first material may include a first input as described herein that allows passage of cells into the electroporation chamber. The lower micromesh electrode may be surrounded by a second material. The second material may include a first output as described herein that allows passage of electroporated cells out of the electroporation chamber. The first input and the first output are separated by an offset distance as described herein. The cells may be suspended in electroporation medium. Optionally, the upper micromesh electrode may further include a second input as described herein, and / or the lower micromesh electrode may further include a second output as described herein.

[0124] In any embodiment, the flow of cells and cargo may be performed in a stepwise manner. For example, a flow rate of about half or more of the total volume of the electroporation chamber may be pumped into the electroporation chamber at a specified time interval. In some embodiments, a flow rate approximately equal to the total volume of the electroporation chamber may be pumped into the electroporation chamber. FIG. 5 shows an example of a series of electrical pulses (stimuli) and an example of a stepwise fluid flow scheme (pump). For the stepwise fluid flow scheme, the chamber volume is about 22 μL. Every second, 11 μL is pumped into the electroporation chamber to replace half the flow rate. This may be repeated for as long as it takes to process the desired amount of cells.

[0125] Additionally or alternatively, any suitable time interval may be used with any amount suitable for a stepwise fluid flow scheme. For example, the time interval may range from about 0.1 seconds to about 10 seconds, about 0.5 seconds to about 5 seconds, about 1 second to about 2 seconds, or any time therebetween, or may include longer intervals. In some embodiments, the amount of fluid pumped into the electroporation chamber as a function of time may be three-quarters the volume of the input chamber, one-half the volume of the electroporation chamber, one-quarter the volume of the electroporation chamber, one-eighth the volume of the electroporation chamber, or less. Any suitable flow rate of cells and cargo may be used with the parameters described herein. For example, the flow rate of the cells and cargo in the electroporation medium may be about 0.1 ml / min or more, about 0.5 ml / min or more, about 1 ml / min or more, about 2.5 ml / min or more, about 5 ml / min or more, about 7.5 ml / min or more, about 10 ml / min or more, about 12.5 ml / min or more, or about 15 ml / min or more, or about 0.1 ml / min to about 15 ml / min, about 0.5 ml / min to about 15 ml / min, about 1 ml / min to about 15 ml / min, about 1 ml / min to about 12.5 ml / min, about 1 ml / min to about 10 ml / min, about 1 ml / min to about 7.5 ml / min, about 1 ml / min to about 5 ml / min, or about 1 ml / min to about 2.5 ml / min.

[0126] In any embodiment, the cells are exposed to a uniform or substantially uniform electric field in the electroporation chamber. Multiple electric pulses may be applied to the cells in the electroporation chamber, where each electric pulse is the same or different. In some embodiments, direct current (DC) electric pulses are applied. Additionally or alternatively, alternating current (AC) electric pulses are applied. In any embodiment, each pulse may have the form of an exponential ejection waveform or a square waveform. In any embodiment, the multiple electric pulses may include both an exponential ejection waveform and a square waveform.

[0127] For a train of electrical pulses, a voltage may be applied to the electrodes every 100ms to 5000ms (e.g., every 100ms, 250ms, 500ms, 1000ms, 2000ms, 3000ms, etc.) to generate an electric field of a given strength. This may be repeated for as long as it takes to process a desired amount of cells. Thus, while an embodiment may be referred to as continuous flow, it is understood that continuous flow includes a step-wise fluid flow scheme, where fluid is continuously pumped into the electroporation chamber according to a predetermined time interval.

[0128] Additionally or alternatively, any suitable duration between electrical pulses may be used with any suitable duration of electrical pulses to the cells in the electroporation chamber, for example, the duration between each pulse may range from about 0.1 seconds to about 15 seconds, about 0.1 seconds to about 10 seconds, about 0.1 seconds to about 5 seconds, about 0.2 seconds to about 1 second, about 0.4 seconds to about 0.6 seconds, or any time therebetween, including longer intervals. In some embodiments, the duration of the electrical pulse may be in the range of about 10 ms to about 10 s, about 10 ms to about 5 s, about 10 ms to about 1 s, about 10 ms to about 500 ms, about 10 ms to about 250 ms, about 50 ms to about 150 ms, about 75 ms to about 125 ms, about 100 ms to about 10 s, about 100 ms to about 5, about 100 ms to about 1 s, about 100 ms to about 500 ms, about 100 ms to about 250 ms, or any range therebetween.

[0129] With regard to suitable numbers of pulses and intervals between pulses, at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 pulses may provide more desirable results than a single pulse. Thus, it is contemplated that the pulses may range from 2 to 10 pulses, 2 to 6 pulses, 6 to 8 pulses, or 2 to 3 pulses. Most typically, pulses are separated from successive pulses by a relatively short interval, typically between 0.5 seconds and 15 seconds, although longer intervals may be used in some cases.

[0130] In any embodiment, the voltage may be from about 0.1 kV / cm to about 5 kV / cm, from about 0.1 kV / cm to about 3 kV / cm, from about 0.1 kV / cm to about 2 kV / cm, from about 0.1 kV / cm to about 1 kV / cm, from about 0.1 kV / cm to about 0.5 kV / cm, from about 0.3 kV / cm to about 5 kV / cm, from about 0.3 kV / cm to about 3 kV / cm, from about 0.3 kV / cm to about 2 kV / cm, from about 0.3 kV / cm to about 1 kV / cm, or from about 0.3 kV / cm to about 0 Multiple electrical pulses may be applied at voltages suitable to generate a field strength of about 0.5 kV / cm, about 0.5 kV / cm to about 3 kV / cm, about 0.5 kV / cm to about 2 kV / cm, about 0.5 kV / cm to about 1 kV / cm, about 0.8 kV / cm to about 3 kV / cm, about 0.8 kV / cm to about 2 kV / cm, about 0.8 kV / cm to about 1 kV / cm, about 1 kV / cm to about 3 kV / cm, or about 1 kV / cm to about 2 kV / cm. Suitable voltages may be about 10V, about 15V, about 20V, about 30V, about 40V, about 50V, about 75V, about 100V, or about 200V, or about 10V to about 200V, about 10V to about 100V, about 10V to about 75V, about 10V to about 50, about 10V to about 40V, about 10V to about 30V, about 15V to about 200V, about 15V to about 100V, about 15V to about 75V, about 15V to about 50, about 15V to about 40V, about 15V to about 30V, about 20V to about 50, about 20V to about 40V, about 20V to about 30V, about 30V to about 50V, about 30V to about 40V, or any suitable range therein.

[0131] Additionally or alternatively, each electrical pulse may be about 10 μs or more, about 50 μs or more, about 75 μs or more, about 100 μs or more, about 250 μs or more, about 500 μs or more, about 750 μs or more, about 1,000 μs or more, about 5,000 μs or more, or about 10,000 μs; or about 10 μs to about 10,000 μs, about 10 μs to about 5,000 μs, about 10 μs to about 1,000 μs, about 10 μs to about 750 μs, about 10 μs to about 50 The pulse width may be 0 μs, about 10 μs to about 250 μs, about 10 μs to about 100 μs, about 10 μs to about 50 μs, about 100 μs to about 1000 μs, about 100 μs to about 750 μs, about 100 μs to about 500 μs, about 100 μs to about 250 μs, about 250 μs to about 1000 μs, about 250 μs to about 750 μs, about 250 μs to about 500 μs, about 500 μs to about 1000 μs, or about 500 μs to about 750 μs.

[0132] Any suitable cell, e.g., mammalian cells, non-mammalian cells, or both, may be transfected with the cargo. Examples of suitable mammalian cells include, but are not limited to, NK cells (e.g., haNK cells, primary NK cells, activated (aNK) cells), EC-7 cells (a derivative of HEK293 cells modified to produce adenovirus), T cells (e.g., primary CD4 / CD8 T cells), CHO-S cells, dendritic cells, embryonic cells, stem cells (e.g., adipose-derived mesenchymal stem cells (AD-MSC)), epithelial cells, lymphocytes, macrophages, gametocytes, and fibroblasts. Examples of suitable non-mammalian cells include, but are not limited to, bacterial cells, and yeast cells. Any suitable cargo, e.g., nucleic acids, may be used. The nucleic acid may be RNA (e.g., synthetic RNA, mRNA, in vitro transcribed RNA, GFP-mRNA, etc.) and / or DNA (e.g., synthetic DNA, GFP-DNA, plasmid DNA, etc.). In particular, NK cells, EC-7 cells (a derivative of HEK293 cells modified to produce adenovirus) and T cells can be transfected with RNA (e.g., synthetic RNA, mRNA, in vitro transcribed RNA, GFP-mRNA, etc.) and / or DNA (e.g., synthetic DNA, GFP-DNA, plasmid DNA, etc.) using the electroporation device described herein. It is further contemplated herein that the electroporation device described herein can be used to perform in vitro fertilization. For example, eggs and sperm can be flowed through an electroporation device as described herein to achieve fertilization of the eggs.

[0133] In further contemplated aspects, the medium or electroporation buffer in which the cells are transfected is a medium of low conductivity and low osmolality, optionally containing one or more nutrients. In any embodiment, the electroporation medium has a conductivity of about 0.05 mS / m or more, about 1 mS / m or more, about 5 mS / m or more, about 10 mS / m or more, about 15 mS / m or more, about 25 mS / m or more, about 30 mS / m or more, about 50 mS / m or more, about 100 mS / m or more, about 150 mS / m or more, or about 200 mS / m or more. or more; or from about 0.05 mS / m to about 200 mS / m; from about 1 mS / m to about 30 mS / m, from about 1 mS / m to about 20 mS / m, from about 1 mS / m to about 10 mS / m, from about 1 mS / m to about 5 mS / m, from about 3 mS / m to about 30 mS / m, from about 5 mS / m to about 20 mS / m, or from about 5 mS / m to about 15 mS / m. Additionally or alternatively, the electroporation medium may have a pH of about 50 mOsm / l or more, about 100 mOsm / l or more, about 150 mOsm / l or more, about 200 mOsm / l or more, about 250 mOsm / l or more, about 300 mOsm / l or more, about 350 mOsm / l or more, or about 400 mOsm / l; or about 50 mOsm / l to about 400 mOsm / l, about 50 mOsm / l to about 300 mOsm / l. , about 50 mOsm / l to about 200 mOsm / l, about 100 mOsm / l to about 400 mOsm / l, about 100 mOsm / l to about 300 mOsm / l, about 200 mOsm / l to about 400 mOsm / l, about 200 mOsm / l to about 300 mOsm / l, about 250 mOsm / l to about 400 mOsm / l, or about 250 mOsm / l to about 300 mOsm / l.

[0134] In any embodiment, the electroporation medium may include one or more salts, sugars, and buffers. Suitable salts include, but are not limited to, metal halide salts, phosphate salts, metal sulfate salts, and combinations thereof. Examples of suitable metal halide salts include, but are not limited to, potassium chloride (KCl), sodium chloride (NaCl), lithium chloride (LiCl), calcium chloride (CaCl2), chromium chloride (CrCl3), potassium bromide (KBr), sodium bromide (NaBr), magnesium chloride (MgCl2), magnesium bromide (MgBr2), magnesium fluoride (MgF2), magnesium iodide (MgI2), lithium bromide (LiBr), potassium iodide (KI), sodium iodide (NaI), and lithium iodide (LiI). Examples of suitable phosphates include, but are not limited to, monosodium phosphate (NaH2PO4), disodium phosphate (Na2HPO4), trisodium phosphate (Na3PO4), monomagnesium phosphate (Mg(H2PO4)2), dimagnesium phosphate (MgHPO4), trimagnesium phosphate (Mg3(PO4)2, monopotassium phosphate (KH2PO4), dipotassium phosphate (K2HPO4), tripotassium phosphate (K3PO4), monocalcium phosphate (Ca(H2PO4)2), dicalcium phosphate (CaHPO4), phosphorus phosphate (Pb(H2PO4)2 ... Suitable metal sulfates include, but are not limited to, sodium sulfate (NaSO), magnesium sulfate (MgSO), potassium sulfate (KSO), calcium sulfate (CaSO), and chromium sulfate (Cr(SO)). In some embodiments, the one or more salts may be potassium chloride, magnesium chloride, disodium phosphate, monopotassium phosphate, magnesium sulfate, and combinations thereof.

[0135] Examples of suitable sugars include monosaccharides, disaccharides, or combinations thereof. Suitable monosaccharides include, but are not limited to, glucose, fructose, and galactose. Suitable disaccharides include, but are not limited to, disaccharides formed from two of glucose, fructose, and galactose. For example, suitable disaccharides can be sucrose, lactose, maltose, trehalose, or combinations thereof. Examples of suitable buffers include, but are not limited to, HEPES, Tris(hydroxymethyl), and PBS (phosphate buffered saline).

[0136] In any embodiment, each of the one or more salts may be present in the electroporation medium at a concentration of about 0.1 mM to about 200 mM, about 0.1 mM to about 150 mM, about 0.1 mM to about 100 mM, about 0.1 mM to about 80 mM, about 0.1 mM to about 60 mM, about 0.1 mM to about 40 mM, about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 1 mM to about 20 mM, or about 1 mM to about 10 mM. For example, salts such as KH2PO4, Na2HPO4, and MgSO4 may be present in the electroporation medium at a concentration of about 0.1 mM to about 20 mM. The sugar may be present in the electroporation medium at a concentration of about 20 mM to about 300 mM, about 20 mM to about 200 mM, or about 40 mM to about 200 mM. The buffer may be present in the electroporation medium at a concentration of about 1 mM to about 100 mM, about 10 mM to about 50 mM, or about 15 mM to about 30 mM.

[0137] Other suitable media include, but are not limited to, Cw100 (0.11 S / m, 0.12 osm / l) or Cw240, as shown in Table 1. Commercially available electroporation media may be utilized, but have been shown to be suboptimal. Such commercially available media include RPMI (1.37 S / m, 0.28 osm / l), BTX (8 mS / m, 0.27 osm / l), DMEM (Dulbecco's Modified Eagle Medium), diluted PBS, or PBS, with or without Hepes. Media are generally conductive media and may be sterilized.

[0138] [Table 1]

[0139] In any embodiment, the cells for electroporation are about 1×10 6 cells / ml or more, approximately 10 x 10 6 cells / ml or more, approximately 50 x 10 6 cells / ml or more, approximately 100 x 10 6 cells / ml or more, approximately 150 x 10 6 cells / ml or more, approximately 200 x 10 6 cells / ml or more, approximately 250 x 10 6 cells / ml or more, approximately 300 x 10 6 cells / ml or more, approximately 400 x 10 6 cells / ml or more, or approximately 500 x 10 6 cells / ml; or approximately 1 x 10 6 Cells / ml ~ approx. 300 x 10 6 cells / ml, approximately 1 x 10 6 Cells / ml ~ approx. 250 x 10 6 cells / ml, approximately 1 x 10 6 Cells / ml ~ approx. 200 x 10 6 cells / ml, approximately 1 x 10 6 Cells / ml ~ approx. 150 x 10 6 cells / ml, approximately 1 x 10 6 Cells / ml ~ approx. 100 x 10 6 cells / ml, approximately 1 x 10 6 Cells / ml ~ approx. 50 x 10 6 cells / ml, approximately 1 x 10 6 Cells / ml ~ approx. 300 x 10 6 cells / ml, approximately 1 x 10 6 Cells / ml ~ approx. 250 x 10 6 cells / ml, approximately 10 x 10 6 Cells / ml ~ approx. 200 x 10 6 cells / ml, approximately 10 x 10 6 Cells / ml ~ approx. 150 x 10 6 cells / ml, approximately 10 x 10 6 Cells / ml ~ approx. 100 x 106 cells / ml, approximately 10 x 10 6 Cells / ml ~ approx. 50 x 10 6 cells / ml, approximately 100 x 10 6 Cells / ml ~ approx. 300 x 10 6 cells / ml, approximately 100 x 10 6 Cells / ml ~ approx. 250 x 10 6 cells / ml, approximately 100 x 10 6 Cells / ml ~ approx. 200 x 10 6 cells / ml, or approximately 100 x 10 6 Cells / ml ~ approx. 150 x 10 6 The cells may be present in the electroporation medium at a cell density of 10 cells / ml.

[0140] With regard to suitable capacitances, it is contemplated that the capacitance may range from about 1 μF to about 150 μF. In some embodiments, the capacitance may range from about 1 to about 100 μF, about 5 to about 75 μF, about 5 to about 50 μF, about 10 to about 40 μF, or about 10 to about 30 μF, or about 10 to about 25 μF. In other embodiments, the capacitance is about 10 μF.

[0141] In some embodiments, multiple electrical pulses may be utilized with corresponding short time constants. In some aspects, time constants of less than 30 ms, less than 20 ms, less than 10 ms, or less than 5 ms may be used. In other aspects, the time constants may range from about 0.5 to 30 ms, about 1 to 20 ms, and about 5 to 15 ms; or about 10 ms.

[0142] In some embodiments, the electric field strength for electroporation is between about 0.3-3 kV / cm. Lower electric field strengths (e.g., about 0.5-1 kV / cm) have been found to be suitable for EC-7 cells, while higher electric field strengths (e.g., about 1-3 kV / cm) have been found to be suitable for Hank cells. In general, electric field strengths for electroporation ranging from about 0.1 to about 5 kV / cm are contemplated herein. The voltage may be selected to generate a suitable electric field strength.

[0143] In general, the impedance (Rp) may range from about 200 Ω to infinity, or otherwise from about 200 Ω up to about 1k.

[0144] The concentration of the cargo added to the electroporation reaction, e.g., the material to be transported into the cell, is about 50 μg / ml or more, about 100 μg / ml or more, about 200 μg / ml or more, about 300 μg / ml or more, about 400 μg / ml or more, or about 500 μg / ml or more; about 50 μg / ml to about 500 μg / ml, about 50 μg / ml to about 400 μg / ml, about 50 μg / ml to about 300 μg / ml, about 50 μg / ml to about 200 μg / ml, about 50 μg / ml to about 100 μg / ml, about 100 μg / ml to about 500 μg / ml, about 100 μg / ml to about 400 μg / ml, about 100 μg / ml to about 300 μg / ml, or about 100 μg / ml to about 200 μg / ml. In some aspects, GFP-mRNA or GFP-DNA was added to the electroporation medium at a concentration of about 50 μg / ml, 60 μg / ml, 100 μg / ml, 200 μg / ml, 100-300 μg / ml, 50-100 μg / ml, while in other embodiments, Dextran 500k was added to the electroporation reaction at a concentration of about 50 μg / ml.

[0145] In some embodiments, 4×10 7 cells / mL (13.2 mL (5.28 x 10 8 A maximum of 7.33uL / s can be achieved within 30 minutes with 20×10 cells. 9 To achieve this, the cell density may be increased four-fold and / or parallel processing may be performed using multiple electroporation chambers.

[0146] In some embodiments and further examples provided below, electroporation electronics and parameters may be designed specifically for electroporation of NK cells (e.g., haNK cells, primary NK cells, activated (aNK) cells), EC7 cells, dendritic cells, CHO-S cells, T cells (e.g., primary CD4 / CD8 T cells), and stem cells (e.g., AD-MSC cells).

[0147] In some embodiments, the cells are one or more of NK cells (e.g., haNK cells, primary NK cells, activated (aNK) cells), EC7 cells, dendritic cells, CHO-S cells, T cells (e.g., primary CD4 / CD8 T cells), and stem cells (AD-MSC cells), and one or more of the electroporation parameters are as follows: (i) the electric field strength is applied at a voltage of about 20 V to about 50 V; (ii) the pulse width is about 10 μs to about 750 μs; and (iii) the cell density of the cells in the electroporation medium is about 5×10 6 Cells / ml ~ approx. 300 x 10 6 cells / ml.

[0148] In some embodiments, the cells are EC-7 cells, the cargo is DNA, and one or more of the electroporation parameters are as follows: (i) the electric field strength is applied at a voltage of about 20 V to about 50 V, about 20 V to 40 V, or about 20 V to about 30 V; (ii) the pulse width is about 10 μs to about 100 μs, 10 μs to about 75 μs, or 10 μs to about 50 μs; (iii) the number of pulses is 2 to 6 or 2 to 3, and (iv) the cell density of the cells in the electroporation medium is about 10×10 6 Cells / ml ~ approx. 250 x 10 6 cells / ml, approximately 10 x 10 6 Cells / ml ~ approx. 100 x 10 6 cells / ml, or approximately 50 x 10 6 Cells / ml ~ approx. 100 x 10 6cells / ml. Additionally or alternatively, the EC-7 cells electroporated with the DNA cargo may have a transfection efficiency of at least about 70%, at least about 80%, or at least about 95% with a viability of at least about 60%, at least about 70%, or at least about 80%.

[0149] In some embodiments, the cells are CHO-S cells, the cargo is DNA, and one or more of the electroporation parameters are as follows: (i) the electric field strength is applied at a voltage of about 20 V to about 50 V, or about 30 V to about 50 V, or about 40 V to about 50 V; (ii) the pulse width is about 100 μs to about 750 μs, about 250 μs to about 750 μs, or about 500 μs to about 750 μs; (iii) the number of pulses is 2 to 6 or 2 to 3; and (iv) the cell density of the cells in the electroporation medium is about 50×10 6 Cells / ml ~ approx. 250 x 10 6 cells / ml, approximately 50 x 10 6 Cells / ml ~ approx. 125 x 10 6 cells / ml, or approximately 50 x 10 6 Cells / ml ~ approx. 100 x 10 6 Additionally or alternatively, the CHO-S cells electroporated with the DNA cargo may have a transfection efficiency of at least about 70%, at least about 80%, or at least about 85% with a viability of at least about 60%, at least about 70%, at least about 80%, or at least about 90%.

[0150] In some embodiments, the cells are T cells (e.g., primary CD4 / CD8 T cells), the cargo is DNA or RNA, and one or more of the electroporation parameters are as follows: (i) the electric field strength is applied at a voltage of about 20 V to about 50 V, or about 30 V to about 50 V, or about 40 V to about 50 V; (ii) the pulse width is about 100 μs to about 750 μs, about 100 μs to about 500 μs, or about 200 μs to about 400 μs; (iii) the number of pulses is 2 to 10 or 2 to 6, and (iv) the cell density of the cells in the electroporation medium is about 10×10 6 Cells / ml ~ approx. 300 x 10 6 cells / ml, approximately 20 x 10 6 Cells / ml ~ approx. 250 x 10 6 cells / ml, or approximately 10 x 10 6 Cells / ml ~ approx. 200 x 10 6 Additionally or alternatively, T cells (e.g., primary CD4 / CD8 T cells) electroporated with DNA or RNA cargo may have a viability of at least about 60%, at least about 70%, at least about 80%, or at least about 90%, with a transfection efficiency of at least about 20%, at least about 80%, at least about 90%, or at least about 99%.

[0151] In some embodiments, the cells are NK cells (e.g., haNK cells, primary NK cells, activated (aNK) cells), the cargo is DNA or RNA, and one or more of the electroporation parameters are as follows: (i) the electric field strength is applied at a voltage of about 20 V to about 50 V, or about 30 V to 50 V, or about 40 V to about 50 V; (ii) the pulse width is about 100 μs to about 750 μs, about 200 μs to about 750 μs, or about 200 μs to about 600 μs; (iii) the number of pulses is 2 to 6 or 2 to 3; and (iv) the cell density of the cells in the electroporation medium is about 10×10 6 Cells / ml ~ approx. 300 x 10 6 cells / ml, approximately 10 x 10 6 Cells / ml ~ approx. 250 x 10 6 cells / ml, or approximately 10 x 106 Cells / ml ~ approx. 100 x 10 6 Additionally or alternatively, NK cells (e.g., haNK cells, primary NK cells, activated (aNK) cells) electroporated with DNA or RNA cargo may have a viability of at least about 60%, at least about 70%, at least about 80%, or at least about 90%, with a transfection efficiency of at least about 10%, at least about 50%, at least about 80%, at least about 90%, or at least about 95%.

[0152] In some embodiments, the cells are dendritic cells, the cargo is DNA or RNA, and one or more of the electroporation parameters are as follows: (i) the electric field strength is applied at a voltage of about 20 V to about 50 V, or about 30 V to about 50 V, or about 30 V to about 40 V; (ii) the pulse width is about 100 μs to about 750 μs, about 100 μs to about 500 μs, or about 200 μs to about 400 μs; (iii) the number of pulses is 2 to 10 or 6 to 8, and (iv) the cell density of the cells in the electroporation medium is about 10×10 6 Cells / ml ~ approx. 100 x 10 6 cells / ml, approximately 10 x 10 6 Cells / ml ~ approx. 50 x 10 6 cells / ml, or approximately 10 x 10 6 Cells / ml ~ approx. 25 x 10 6 Additionally or alternatively, dendritic cells electroporated with DNA or RNA cargo may have a transfection efficiency of at least about 70%, at least about 80%, or at least about 90% with a viability of at least about 70%, at least about 80%, or at least about 90%.

[0153] In some embodiments, the cells are stem cells (e.g., AD-MSC cells), the cargo is DNA, and one or more of the electroporation parameters are as follows: (i) the electric field strength is applied at a voltage of about 20 V to about 50 V, or about 30 V to about 50 V, or about 30 V to about 40 V; (ii) the pulse width is about 50 μs to about 250 μs, about 50 μs to about 100 μs, or about 100 μs to about 200 μs; (iii) the number of pulses is 2 to 10 or 6 to 8, and (iv) the cell density of the cells in the electroporation medium is about 10×10 6 Cells / ml ~ approx. 100 x 10 6 cells / ml, approximately 10 x 10 6 Cells / ml ~ approx. 50 x 10 6 cells / ml, or approximately 10 x 10 6 Cells / ml ~ approx. 25 x 10 6 Additionally or alternatively, the stem cells (e.g., AD-MSC cells) electroporated with the DNA cargo may have a transfection efficiency of at least about 70%, at least about 80%, or at least about 90% with a viability of at least about 70%, at least about 80%, or at least about 90%.

[0154] The methods described herein can be applied to transient or stable transfection. The term "transient transfection" refers to the introduction or transfection of a nucleic acid that is present in the cell for a limited period of time and is not integrated into the genome. The term "stable transfection" refers to transfection that results in permanent expression of the gene of interest through integration of the transfected nucleic acid into the nuclear genome or maintenance of the transfected plasmid as an extrachromosomal replicating episome in the cell.

[0155] In any embodiment, the methods described herein may further include a first cell sorting step and / or a second cell sorting step, e.g., using a microfluidic device as described herein. The first cell sorting step may involve applying pressure to cause a first solution containing cells to flow through a microfluidic chamber as described herein that includes a plurality of post rows as described herein, deflecting the cells to the side of the chamber by the post rows, depleting the solution exiting a first output mechanism as described herein, and concentrating the cells in the solution exiting a second output mechanism as described herein, whereby the cells may be sorted prior to introduction into the electroporation chamber. The cells exiting the second output mechanism may be introduced into the electroporation chamber along with a cargo. The second cell sorting step can sort the electroporated cells upon exiting the electroporation chamber by applying pressure to cause a fourth solution containing the electroporated cells to flow through a microfluidic chamber as described herein that includes a plurality of rows of posts as described herein, deflecting the electroporated cells to the side of the chamber by the rows of posts, depleting the electroporated cells from the solution exiting a third output mechanism as described herein, and concentrating the electroporated cells in the solution exiting a fourth output mechanism as described herein.

[0156] The techniques and methods provided herein may be incorporated into various devices or platforms as part of a workflow. For example, an electroporation apparatus as described herein may be incorporated into an automated device, e.g., in cartridge form, where electroporation may be performed in conjunction with one or more other automated processes on cells. For example, automated electroporation may be performed in conjunction with automated cell culture and harvesting, as described in U.S. Patent No. 6,399,992, which is incorporated by reference in its entirety.

[0157] In another aspect, a method of in vivo transfection is provided, wherein the method is performed and the transfected cells, for example mixed with an isotonic buffer, may be administered to a patient to treat a disease or disorder. Examples of diseases include, but are not limited to, mitochondrial disorders, cardiac dysfunction, heart failure, autism, diabetes, and hearing loss. It is also contemplated herein that the electroporation device described herein may be adapted for application to a target tissue of a subject to contribute to the delivery of a drug or formulation, for example, to contribute to the delivery of insulin or a drug to treat diabetes. For example, an electrode for electroporation may be applied to the skin surface, or a needle-shaped electrode pair may be administered subcutaneously. It is also contemplated herein that the electroporation device and method may be used for adenovirus production, protein generation, cellular immunotherapy, or regenerative medicine.

[0158] Kits are also provided herein. For example, the kits may include an electroporation device as described herein, a first container for containing cells and cargo to be transfected, a second container for containing electroporated cells, tubing for fluidly connecting the first container and the second container to the electroporation device, and optionally suitable reagents. In some embodiments, the kits may include a first package including a first module (e.g., first module 805) containing, for example, the first container and a first portion of the tubing. The kits may further include a separate second package including, for example, a second module (e.g., second module 815) containing, for example, the electroporation device and a second portion of the tubing. The kits may also include a separate third package including a third module (e.g., third module 825) containing, for example, the second container and a third portion of the tubing. Optionally, the reagents may be present in a separate fourth package. The first, second, third, and fourth packages may be sterilized. Suitable reagents include, but are not limited to, cells to be transfected as described herein, electroporation media as described herein, and combinations thereof. Additionally or alternatively, the kit may further include electroporation tips, connecting tubes, devices, tools for electroporation, electroporation buffers, additives, reagents, and combinations thereof. [Example] Example 1. Transfection of haNK cells In some embodiments, conditions for electroporation of haNK cells are provided in Table 2 below.

[0159] [Table 2]

[0160] Figures 7A-E show experimental results of electroporation reactions. Figure 7A shows various experimental conditions with different efficiencies and viability. In particular, conditions of 1.5 kv / cm, Rp1k, 10 uF using an IOCO electroporation device gave >80% efficiency with >70% viability for electroporation of GFP-mRNA into haNK cells. The designation "reg" refers to the original micromesh, while "offset" refers to the offset micromesh. Figure 7B shows a microscopic image of GFP-mRNA being electroporated into hank cells. Figures 7C and 7D show the results of cell sorting, where Figure 7C shows live cells and Figure 7D shows electroporated cells. Figure 7E shows the histograms corresponding to the cell sorting results, showing control cells and cells electroporated with GFP.

[0161] Figures 8A-8D show another set of experimental results under various electroporation experimental conditions, where electroporation of GFP-mRNA into haNK resulted in an efficiency of over 50% and a viability of over 70%. Figures 8B and 8C show the results of cell sorting, where Figure 8B shows live cells and Figure 8C shows electroporated cells. Figure 8D shows a histogram corresponding to the cell sorting results, showing control cells and cells electroporated with GFP. GFP expression was counted in live cells (propidium iodide negative, PI-). CTL represents the control experiment.

[0162] Example 2. Transfection of EC7 cells Exemplary conditions for electroporation of EC7 cells are shown in Table 3 below.

[0163] [Table 3]

[0164] 9A-9D are experimental results of electroporation reactions in EC-7 cells. FIG. 9A shows various experimental conditions along with various efficiencies and viabilities. In particular, electroporation of GFP-DNA into EC-7 cells with 1 kv / cm, Rp200, 10 uF using an IOCO electroporation device resulted in an efficiency of >90% and a viability of >50%. FIG. 9B-9C show the results of cell sorting, where FIG. 9B shows live cells and FIG. 9C shows electroporated cells. FIG. 9D is a histogram corresponding to the cell sorting results, showing control cells and GFP-electroporated cells.

[0165] Figures 10A-10E show an additional set of experimental results in EC-7 cells under various electroporation experimental conditions. Figures 10B, 10C, and 10D show cell sorting results, where 10B shows live cells and 10C and 10D show electroporated live cells. Figure 10E shows control cells and GFP-electroporated cells along with histograms corresponding to the cell sorting results. GFP expression was counted in live cells (propidium iodide negative, PI-). CTL represents the control experiment.

[0166] Figures 11A-11C show images of GFP-DNA successfully electroporated into EC-7 cells using the electroporation apparatus and offset chamber of Figures 3A-C.

[0167] Figure 11A was obtained 20 hours after electroporation and shows electroporation of GFP-DNA and GFP-AD5 (DNA encoding AD5 viral production) into EC-7 cells. Figure 11B was obtained 44 hours after electroporation and shows electroporation of GFP-DNA and DNA shuttle vector into EC-7 cells. Figure 11C was obtained 6 days after electroporation and shows a comparison of electroporation results on a micromesh versus a cuvette.

[0168] According to embodiments presented herein, Figure 11C also shows comet formation during the early stages of AD5 virus production in EC7 cells. In this series of images, cells form clusters, or "comet"-like plaques, with each cell becoming more rounded.

[0169] As shown by this series of images, EC-7 cells were able to successfully electroporate fluorescently tagged viral DNA (for AD5 virus production) and initiate virus production, demonstrating that the techniques and systems provided herein are suitable for adenovirus production (e.g., for use in viral vaccines and for the production of viral proteins).

[0170] Figures 12A and 12B show further results of transfecting EC7 cells using the methods and devices described herein. Figure 12A shows a table of electroporation parameters when the amount of cargo was varied between electroporation runs. In Figure 12B, images are shown 6 days after electroporation. By 14 days after electroporation, approximately 70-80% efficiency was observed. Multiple "comet"-like clusters were observed after transfection. Approximately 17-18 million cells / min may be transfected into EC7 cells at a cell concentration of approximately 40m / ml in electroporation buffer cw100, which has a conductance of approximately 240mS / m.

[0171] Example 3. Electroporation of various cell types In other embodiments, the methods and systems provided herein may be used to transfect a variety of different cell types. For example, the methods and systems provided herein may be used to transfect up to 10 8 One or more cells can be transfected. The methods and systems provided herein may be used to transfect EC7 cells, haNK cells, CHO cells, and T cells. For example, at a flow rate of 0.6 ml / min and 4×10 7The methods and techniques presented herein may be used to transfect EC7 cells using a cell concentration of 10 cells / ml. In another example, a flow rate of 0.36 ml / min and a cell concentration of 3×10 7 The methods and techniques presented herein may be used to transfect haNK cells using a cell concentration of 10 cells / ml. In yet another example, a flow rate of 0.45 ml / min and a cell concentration of 2.5×10 7 The methods and techniques provided herein may be used to transfect CHO cells using a cell concentration of 10 cells / ml. For T cells, a flow rate of 0.44 ml / min and a cell concentration of approximately 2×10 7 The methods and techniques presented herein may be used to transfect T cells at a cell concentration of cells / ml. These conditions may be further altered to achieve optimal conditions.

[0172] Figures 13A-D show various transfection efficiencies in these different cell lines using the methods and devices described herein. Figure 13A shows a transfection efficiency of over 95% with over 90% cell viability in haNK cells (transfected with GFP mRNA). Up to 127 million cells / min were transfected. Figure 13B shows a transfection efficiency of over 90% with over 50% cell viability in CHO cells (transfected with GFP pmax DNA). Up to 15 million cells / min were transfected. Figure 13C shows a transfection efficiency of over 95% with over 50% cell viability in EC7 cells (transfected with GFP adenovirus DNA). Up to 20 million cells / min or more were transfected. Figure 13D shows a transfection efficiency of over 90% with over 80% cell viability in T cells (transfected with GFP mRNA). Up to 8.8 million cells / min were transfected.

[0173] Example 4. Transfection of primary T cells In another embodiment, the methods and systems presented herein are used to electroporate mRNA attached to poly(β-amino ester) into primary T cells. Certain poly(β-amino ester) polymers have been shown to act as effective RNA transfection agents.

[0174] Nanoparticles comprising RNA and poly(β-amino ester) polymers have been used to deliver mRNA to T cells (see, for example, Non-Patent Document 4). For example, in some embodiments, nanoparticles may be made with a shell based on polyglutamic acid (PGA). To target the nanoparticles to the appropriate target, a targeting molecule (e.g., a binding domain of an antibody) may be attached to the PGA molecule. For example, to target the nanoparticles to T cells, an anti-CD3 / anti-CD28 binding domain may be attached to the PGA molecule. For targeting, PGA or any other suitable negatively charged molecule may be used. Nanoparticle uptake may occur by specific targeting or cationic membrane association.

[0175] The interior of the nanoparticle may contain mRNA and a carrier molecule such as poly(β-amino ester). Once the nanoparticle is taken up into the cell, the mRNA is released into the cell by degradation of the nanoparticle, by osmotic swelling, or by some other suitable process, and the mRNA is transcribed into its respective protein. In some cases, synthetic mRNA may be used to reduce mRNA degradation.

[0176] The methods provided herein may be used to transfect cells with mRNA, for example, by using mRNA and poly(β-amino ester) (PbAE) carriers or nanoparticles encapsulating mRNA and poly(β-amino ester) carriers. Figures 14A-E show T cell transfection using PbAE complexed with mRNA (not free mRNA, not electroporation). Figure 13A shows a poly(β-amino ester) structure suitable for use with the techniques provided herein. Figure 14B shows the results of cell sorting using flow cytometry of T cells transfected with mRNA using PbAE. Figure 14C is a graph showing the results normalized to live cells based on various ratios of mRNA to carrier molecules. Figures 14D and 14E show the results of cell viability under various conditions for GFP-mRNA transfection in stimulated (Figure 14D) and unstimulated (Figure 14E) T cells. In these experiments, a PbAE:RNA ratio of 60:1 resulted in high levels of viable cells while providing high rates of GFP delivery.

[0177] Figures 15A and 15B show GFP mRNA transfection into T cells using control cells (no electroporation) and electroporated cells. In particular, Figure 15A shows control cells (no electroporation), where mainly background fluorescence is observed. Figure 15B shows electroporated cells, where GFP-mRNA is detected in the majority of cells, as shown by the histogram.

[0178] Example 5. Transfection of adipose-derived mesenchymal stem cells (AD-MSCs) Adipose-derived mesenchymal stem cells (AD-MSCs) were added at approximately 1 × 10 5Cells were detached and collected at a density of 1 million cells / milliliter. Cells were washed with PBS and electroporation buffer and suspended in electroporation buffer at a density of 3.3 million cells / milliliter. For each condition, 30 μg of DNA was electroporated at a final cell density of 0.1 milliliter. Electroporation conditions were as follows: pulse width = 100 us, pulse duration = 340 ms, field strength varied from 0.9 to 1.6 kV / cm as shown in Table 4 below.

[0179] [Table 4]

[0180] After electroporation, cells were cultured at 30 × 10 3 Cells / cm 2 The cells were seeded at a density of 1000 x 1000 μg / cm. 24 hours after electroporation, the GFP expression efficiency was verified by flow cytometry. The results are shown in Figures 16A-16D. The x-axis values ​​of 1-8 in each of Figures 16A-16C correspond to the electric field strength as shown in Table 4, and "CTL" corresponds to the control without electroporation. Figure 16A shows the cell viability 24 hours after electroporation. As the electric field strength decreases, the live cells increase. Figure 16B shows the expression of GFP (green fluorescent protein) read by flow cytometry in the measurement of cell transfection efficiency 24 hours after electroporation. As the electric field became stronger, a higher percentage of live cells expressed GFP. Figure 16C shows the median GFP fluorescence, which represents how bright GFP was in the flow cytometry measurement. As the electric field became stronger, more bright GFP was measured. The results suggested that an electric field strength between 1.1-1.3 kv / cm may show the best performance in viability and efficiency. Note that this viability includes both attached cells and supernatants so as to reflect true total viability. Figure 16D shows photos of MSC transfection results. The photo on the left shows the morphology of MSCs, and the image on the right is a fluorescent image in the same light field, showing that the majority of cells express green fluorescent protein (green).

[0181] Example 6. Transfection of EC-7 cells, CHO-S cells, primary CD4 / CD8 T cells, haNK cells, primary NK cells, activated NK cells, dendritic cells, and AD-MSC cells. EC-7 cells, CHO-S cells, primary CD4 / CD8 T cells, haNK cells, primary NK cells, activated NK cells, dendritic cells, and AD-MSC cells were electroporated in an apparatus similar to that depicted in FIG. 2A using the electroporation parameters shown in Table 5 below.

[0182] [Table 5]

[0183] The compositions of electroporation media ("Electro media") 1 and 2 used in Table 5 are shown in Tables 6 and 7 below.

[0184] [Table 6]

[0185] [Table 7]

[0186] The results of electroporating the cells in Table 5 according to the given parameters are presented in Table 8 below.

[0187] [Table 8]

[0188] [Table 9]

[0189] In some embodiments, numbers expressing properties such as amounts of ingredients, concentrations, reaction conditions, and the like, used to describe and claim particular embodiments should be understood to be modified in some instances by the term "about". Accordingly, in some embodiments, the numerical parameters set forth in the specification and appended claims are approximations that may vary depending on the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters must be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments are approximations, the numerical values ​​set forth in the specific examples are reported as precisely as practicable. The numerical values ​​presented in some embodiments may necessarily contain certain errors resulting from the standard deviation found in their respective testing measurements.

[0190] As used in this description and throughout the claims that follow, the meanings of "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Additionally, as used in this description, the meaning of "in" includes "in" and "on," unless the context clearly dictates otherwise. Unless the context dictates otherwise, all ranges set forth herein should be interpreted as inclusive of their endpoints, and open-ended ranges should be interpreted as inclusive of commercially practical values. Similarly, all value lists should be viewed as inclusive of intermediate values, unless the context dictates otherwise.

[0191] It should also be apparent to those skilled in the art that many further modifications beyond those already described herein are possible without departing from the inventive concept herein. Moreover, when interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms "comprises" and "comprising" should be interpreted to refer to elements, components, or steps in a non-exclusive manner, indicating that the referenced element, component, or step may be present or utilized with or combined with other elements, components, or steps not expressly referenced. When a claim herein refers to at least one selected from the group consisting of A, B, C... and N, the text should be interpreted as requiring only one element from that group, not A+N, or B+N, etc. [Explanation of symbols] 100 cells 105 Chamber 110 First input mechanism 112 Second input mechanism 115 Posts 120 First output mechanism 122 Second output mechanism 130 Deflection point 150 Ceiling 155 Upper area 160 beds 165 Lower area 200 IOCO Electroporation Apparatus 210 First Input 220 Electroporation Chamber 230 1st Output 240(1) Lower micromesh electrode 240(2) Upper micromesh electrode 310 External Plate 310-330: Electroporation equipment 330(1) Upper mesh 330(2) Lower mesh 335 Curved Path 350 Syringe 360 Electroporator Pulsar 380 Entrance 390 Exit 410 Cartridge 440(1) 1st electrode 440(2) Second electrode 510 Sample Tube 520 Generation means 530 Electroporation Device 540 Controller 550 Collection Tube 560 Priming Buffer Tube 570 Valve 575 Valve 577 Buffer Selection Tube 580 First Microfluidic Device 585 Second Microfluidic Device 600 Electroporation Device 620 Entrance 630 Exit 640 electrode 700a Electroporation Apparatus 700b Electroporation Apparatus 706 Top Surface 710 First Input 711 Lower Surface 715(1) First material 715(2) Second material 720 Electroporation Chamber 725 Fluid Channel Region 730 1st Output 735 Routes 740(1) 1st electrode 740(2) Second electrode 741(1) 1st electrode 741(2) Second electrode 745 Solid Metal Plate 750 1st external input 760 First external output 800 Modular System 805 1st module 807 1st container 809 Air filter device 810 Tube 815 2nd Module 820 Electroporation Device 825 3rd Module 830 Second container 850 Connector 852 equipment 854 Power supply 856 Power supply 858 Control circuit 860 Electroporation Device 862 Power Converter 864 Pulse Circuit 866 Controller 868 Pulse Generator 870 Feedback Signal 872 Control Signals 874 signal 876 Control Signals 878a signal 878b signal 880 signal 882 signal 884 signal 886 equipment 888 Power supply 890 Control circuit 892 Filters 894 Gate Driver 896 Control Signals [Brief description of the drawings]

[0192] [Figure 1A] A typical electroporation apparatus is shown, which includes parallel plate electrodes (as shown in FIG. 1A) and a micromesh electrode with no offset between the input and output (as shown in FIG. 1B). [Figure 1B] A typical electroporation apparatus is shown, which includes parallel plate electrodes (as shown in FIG. 1A) and a micromesh electrode with no offset between the input and output (as shown in FIG. 1B). [Figure 2A] 1 illustrates aspects of an apparatus for electroporation according to some embodiments provided herein. [Figure 2B] 1 illustrates aspects of an apparatus for electroporation according to some embodiments provided herein. [Figure 2C] 1 illustrates aspects of a first electrode and a second electrode according to some embodiments provided herein. [Figure 2D] FIG. 1 is a block diagram of an apparatus for generating and providing electrical pulses to cells within an electroporation device as described herein, according to some embodiments provided herein. [Figure 2E] FIG. 1 is a block diagram of a further apparatus for generating and providing an electrical pulse to cells within an electroporation apparatus as described herein according to some embodiments provided herein. [Figure 3A] 3A shows an embodiment of an apparatus for electroporation including an electroporation device according to some embodiments provided herein. FIG. 3A shows a diagram of the structure of an input-output chamber offset electroporation device. [Figure 3B] 3A and 3B show an embodiment of an apparatus for electroporation including an electroporation device according to some embodiments provided herein. FIG. 3B shows a diagram of the electric field of the input-output chamber offset electroporation device. [Figure 3C] 3A-3C show aspects of an apparatus for electroporation including an electroporation device according to some embodiments provided herein. FIG. 3C shows electric field strength as a function of cell migration distance through an input-output chamber offset electroporation device. [Figure 3D] 3A and 3B show aspects of an apparatus for electroporation including an electroporation device according to some embodiments provided herein. FIG. 3D shows an alternative arrangement of an electroporation device according to some embodiments provided herein. [Figure 3E]1 illustrates aspects of pathways within an electroporation chamber according to some embodiments provided herein. [Figure 3F] 1 illustrates aspects of pathways within an electroporation chamber according to some embodiments provided herein. [Figure 3G] 1 illustrates aspects of pathways within an electroporation chamber according to some embodiments provided herein. [Figure 3H] 1 illustrates an alternative configuration of an electroporation apparatus according to some embodiments provided herein. [Figure 3I] 1 illustrates an alternative configuration of an electroporation apparatus according to some embodiments provided herein. [Figure 3J] 1 illustrates an alternative configuration of an electroporation apparatus according to some embodiments provided herein. [Figure 3K] 1 illustrates an example microfluidic chamber for sorting cells, according to some embodiments provided herein. [Figure 3L] 1 illustrates an example microfluidic chamber for sorting cells, according to some embodiments provided herein. [Figure 3M] 1A-1C are diagrams illustrating various aspects of post geometry and positioning within a microfluidic chamber in accordance with some embodiments provided herein. [Figure 3N] 1A-1C are diagrams illustrating various aspects of post geometry and positioning within a microfluidic chamber in accordance with some embodiments provided herein. [Figure 3O] 1A-1C are diagrams illustrating various aspects of post geometry and positioning within a microfluidic chamber in accordance with some embodiments provided herein. [Figure 3P] 1A-1C are diagrams illustrating various aspects of post geometry and positioning within a microfluidic chamber in accordance with some embodiments provided herein. [Figure 3Q]1A-1C are diagrams illustrating various aspects of post geometry and positioning within a microfluidic chamber in accordance with some embodiments provided herein. [Figure 3R] 1A-1C are diagrams illustrating various aspects of post geometry and positioning within a microfluidic chamber in accordance with some embodiments provided herein. [Figure 3S] 1A-1C are diagrams illustrating various aspects of post geometry and positioning within a microfluidic chamber in accordance with some embodiments provided herein. [Figure 3T] 1 illustrates an example microfluidic chamber for changing buffer solutions, according to some embodiments provided herein. [Figure 3U] FIG. 1 illustrates an example microfluidic chamber having two separate chambers, one for cell sorting and another for buffer change, according to some embodiments provided herein. [Figure 3V] 1 illustrates an alternative configuration of an electroporation apparatus according to some embodiments provided herein. [Figure 3W] 1 illustrates an alternative configuration of an electroporation apparatus according to some embodiments provided herein. [Figure 3X] 1 illustrates a modular arrangement of an electroporation system including an electroporation apparatus according to some embodiments provided herein. [Figure 4] 1 shows a table of parameters associated with a chamber offset electroporation apparatus according to some embodiments provided herein. [Diagram 5] 1A-1D show examples of fluid flow waveforms (pumps) and electrical waveforms (stimuli) that may be applied to cells flowing through a chamber offset electroporation apparatus according to some embodiments provided herein. [Figure 6]1A-1C show various examples of micromeshes formed of different materials suitable for use in a chamber offset electroporation apparatus according to some embodiments provided herein. [Figure 7A] 1 shows the results of electroporation experiments on haNK cells and corresponding parameters using the methods and devices described herein. [Figure 7B] 1 shows the results of electroporation experiments on haNK cells and corresponding parameters using the methods and devices described herein. [Figure 7C] 1 shows the results of electroporation experiments on haNK cells and corresponding parameters using the methods and devices described herein. [Figure 7D] 1 shows the results of electroporation experiments on haNK cells and corresponding parameters using the methods and devices described herein. [Figure 7E] 1 shows the results of electroporation experiments on haNK cells and corresponding parameters using the methods and devices described herein. [Figure 8A] 13 shows further results of electroporation experiments on haNK cells and corresponding parameters using the methods and devices described herein. [Figure 8B] 13 shows further results of electroporation experiments on haNK cells and corresponding parameters using the methods and devices described herein. [Figure 8C] 13 shows further results of electroporation experiments on haNK cells and corresponding parameters using the methods and devices described herein. [Figure 8D] 13 shows further results of electroporation experiments on haNK cells and corresponding parameters using the methods and devices described herein. [Figure 9A] 1 shows the results of electroporation experiments on EC7 cells and corresponding parameters using the methods and devices described herein. [Figure 9B] 1 shows the results of electroporation experiments on EC7 cells and corresponding parameters using the methods and devices described herein. [Figure 9C] 1 shows the results of electroporation experiments on EC7 cells and corresponding parameters using the methods and devices described herein. [Figure 9D] 1 shows the results of electroporation experiments on EC7 cells and corresponding parameters using the methods and devices described herein. [Figure 10A] 1 shows further results of electroporation experiments on EC7 cells and corresponding parameters using the methods and devices described herein. [Figure 10B] 1 shows further results of electroporation experiments on EC7 cells and corresponding parameters using the methods and devices described herein. [Figure 10C] 1 shows further results of electroporation experiments on EC7 cells and corresponding parameters using the methods and devices described herein. [Figure 10D] 1 shows further results of electroporation experiments on EC7 cells and corresponding parameters using the methods and devices described herein. [Figure 10E] 1 shows further results of electroporation experiments on EC7 cells and corresponding parameters using the methods and devices described herein. [Figure 11A] Shown is a microscopic image of electroporated EC7 cells. [Figure 11B] Shown is a microscopic image of electroporated EC7 cells. [Figure 11C] Shown is a microscopic image of electroporated EC7 cells. [Figure 12A] Further results are presented for transfected EC7 cells using the methods and devices described herein. [Figure 12B]Further results are presented for transfected EC7 cells using the methods and devices described herein. [Figure 13A] 1 shows the various transfection efficiencies in different cell lines using the methods and devices described herein. [Figure 13B] 1 shows the various transfection efficiencies in different cell lines using the methods and devices described herein. [Figure 13C] 1 shows the various transfection efficiencies in different cell lines using the methods and devices described herein. [Figure 13D] 1 shows the various transfection efficiencies in different cell lines using the methods and devices described herein. [Figure 14A] 1 shows the results of a transfection experiment using PbAE as described herein to introduce mRNA into T cells. [Figure 14B] 1 shows the results of a transfection experiment using PbAE as described herein to introduce mRNA into T cells. [Figure 14C] 1 shows the results of a transfection experiment using PbAE as described herein to introduce mRNA into T cells. [Figure 14D] 1 shows the results of a transfection experiment using PbAE as described herein to introduce mRNA into T cells. [Figure 14E] 1 shows the results of a transfection experiment using PbAE as described herein to introduce mRNA into T cells. [Figure 15A] As described herein, the results of transfection experiments to introduce mRNA into T cells in the presence and absence of electroporation are shown. [Figure 15B] As described herein, the results of transfection experiments to introduce mRNA into T cells in the presence and absence of electroporation are shown. [Figure 16A]1 shows the results of transfection experiments on adipose-derived mesenchymal stem cells (AD-MSCs) and corresponding parameters using the methods and devices described herein. [Figure 16B] 1 shows the results of transfection experiments on adipose-derived mesenchymal stem cells (AD-MSCs) and corresponding parameters using the methods and devices described herein. [Figure 16C] 1 shows the results of transfection experiments on adipose-derived mesenchymal stem cells (AD-MSCs) and corresponding parameters using the methods and devices described herein. [Figure 16D] 1 shows the results of transfection experiments on adipose-derived mesenchymal stem cells (AD-MSCs) and corresponding parameters using the methods and devices described herein.

Claims

1. An electroporation medium, comprising: one or more metal halide salts selected from the group consisting of potassium chloride (KCl), sodium chloride (NaCl), lithium chloride (LiCl), calcium chloride (CaCl2), chromium chloride (CrCl3), potassium bromide (KBr), sodium bromide (NaBr), magnesium chloride (MgCl2), magnesium bromide (MgBr2), magnesium fluoride (MgF2), magnesium iodide (MgI2), lithium bromide (LiBr), potassium iodide (KI), sodium iodide (NaI), lithium iodide (LiI), and combinations thereof; a phosphate salt selected from the group consisting of monosodium phosphate (NaH2PO4), disodium phosphate (Na2HPO4), trisodium phosphate (Na3PO4), monomagnesium phosphate (Mg(H2PO4)2), dimagnesium phosphate (MgHPO4), trimagnesium phosphate (Mg3(PO4)2), monopotassium phosphate (KH2PO4), dipotassium phosphate (K2HPO4), tripotassium phosphate (K3PO4), monocalcium phosphate (Ca(H2PO4)2), dicalcium phosphate (CaHPO4), tricalcium phosphate (Ca3(PO4)2), chromium phosphate (CrPO4), and combinations thereof; a monosaccharide present in the electroporation medium at a concentration of about 40 mM to about 200 mM; and A buffer selected from the group consisting of HEPES, Tris(hydroxymethyl), phosphate buffered saline (PBS), and combinations thereof; Electroporation medium comprising:

2. 2. The electroporation medium of claim 1, wherein each of the metal halide salt and the phosphate salt is present in the electroporation medium at a concentration of about 0.1 mM to about 200 mM, and the buffering agent is present in the electroporation medium at a concentration of about 1 mM to about 100 mM, and / or the electroporation medium has a conductivity of 1 mS / m to about 20 mS / m and an osmolality of about 50 mOsm / l to about 300 mOsm / l.

3. The electroporation medium of claim 1 or 2, wherein the monosaccharide is selected from the group consisting of glucose, fructose, galactose, and combinations thereof.

Images